{"gene":"SNCA","run_date":"2026-04-28T20:42:08","timeline":{"discoveries":[{"year":1993,"finding":"SNCA (NACP) was molecularly cloned as the precursor of NAC (non-Aβ component of AD amyloid), a 140-amino-acid protein (Mr ~19 kDa) found in the cytosolic fraction of brain homogenates and identified as a second component of purified AD amyloid; its NAC peptide sequence has strong β-structure-forming tendency consistent with amyloid association.","method":"cDNA cloning, amino acid sequencing, immunoblot, immunohistochemistry, secondary structure prediction","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — original molecular cloning with biochemical validation, foundational paper >1000 citations","pmids":["8248242"],"is_preprint":false},{"year":1996,"finding":"Human NACP/α-synuclein is a natively unfolded protein: it has a Stokes radius (34 Å) and sedimentation coefficient (1.7S) inconsistent with a globular fold, lacks significant secondary structure by CD and FTIR, has no hydrophobic core, and exists as rapidly equilibrating extended conformers—properties unchanged by boiling, pH, salt, or denaturants.","method":"Analytical ultracentrifugation, circular dichroism (CD), FTIR, UV spectroscopy, gel filtration","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal biophysical methods, >1200 citations, foundational structural characterization","pmids":["8901511"],"is_preprint":false},{"year":1996,"finding":"NACP/α-synuclein is a presynaptic protein colocalized with synaptophysin-immunoreactive structures; in Alzheimer's disease brain its concentration per synaptic structure increases while overall synaptic number decreases, and NAC immunoreactivity is found in the amyloid core of neuritic/diffuse plaques, implicating SNCA in amyloid formation.","method":"Semiquantitative immunoblot, confocal immunofluorescence, computer-aided morphometry","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 3 — immunohistochemical localization with quantitative morphometry, replicated in multiple brain regions","pmids":["8546207"],"is_preprint":false},{"year":1995,"finding":"The SNCA/NACP gene is the human homolog of rat synuclein, maps to chromosome 4, and is expressed as at least three alternatively spliced transcripts in lymphocytes; sequencing the entire coding region in 26 familial early-onset AD patients found no mutations.","method":"Homology search, chromosomal mapping, RT-PCR, direct sequencing","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 — genetic mapping with sequencing, foundational genomic characterization","pmids":["7601450"],"is_preprint":false},{"year":1997,"finding":"A missense mutation (A53T) in the SNCA gene co-segregates with autosomal dominant Parkinson's disease in an Italian kindred and three unrelated Greek families, identifying SNCA as the first gene causally linked to PD.","method":"Linkage analysis, mutation screening by sequencing, family-based genetic study","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 — co-segregation in multiple independent families, >6600 citations, foundational discovery","pmids":["9197268"],"is_preprint":false},{"year":1997,"finding":"NACP/α-synuclein immunoreactivity is present in Lewy bodies and degenerating neurites in sporadic Parkinson's disease brain; all ubiquitin-immunoreactive Lewy bodies are also NACP-immunoreactive, establishing SNCA as a core component of Lewy bodies.","method":"Immunohistochemistry with anti-NACP and anti-ubiquitin antibodies on serial sections","journal":"Neuroscience letters","confidence":"High","confidence_rationale":"Tier 2 — double-label immunohistochemistry on serial sections, replicated across multiple PD cases","pmids":["9547168"],"is_preprint":false},{"year":1997,"finding":"NACP/α-synuclein expression is upregulated during phorbol ester-induced megakaryocytic differentiation in K562 cells while β-synuclein is downregulated; in platelets, NACP is loosely associated with the plasma membrane, endomembrane system, and membranes of secretory α-granules, demonstrating membrane association in a non-neuronal context.","method":"Immunoblot, immunogold electron microscopy, cell differentiation assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — direct subcellular localization by immunogold EM with differentiation context","pmids":["9299413"],"is_preprint":false},{"year":1998,"finding":"A30P mutation in SNCA is identified in a German family with Parkinson's disease, establishing a second causative point mutation in α-synuclein.","method":"Mutation screening/sequencing, family genetic study","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — co-segregation in PD family, independently replicated disease-causing mutation","pmids":["9462735"],"is_preprint":false},{"year":1998,"finding":"NACP/α-synuclein shows transient upregulation and redistribution around cerebral blood vessels after 5-min ischemia in gerbil hippocampal CA1 subfield, with development of unusual tubal and chain-like NACP-positive structures at 6 months, implicating SNCA in ischemic pathogenesis.","method":"Immunohistochemistry at multiple time points after ischemia","journal":"Brain research","confidence":"Low","confidence_rationale":"Tier 3 — single-method immunohistochemical observation, single lab","pmids":["9555070"],"is_preprint":false},{"year":2001,"finding":"Expression of human α-synuclein in Drosophila causes dopaminergic neuron loss; directed expression of the molecular chaperone Hsp70 prevented this neuronal loss, and inhibition of endogenous chaperone activity accelerated α-synuclein toxicity—demonstrating that chaperone activity modulates SNCA-mediated neurodegeneration.","method":"Transgenic Drosophila, directed expression, dopaminergic neuron counting, genetic epistasis","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in established model organism, bidirectional chaperone manipulation, ~1000 citations","pmids":["11823645"],"is_preprint":false},{"year":2001,"finding":"Dopamine and related catecholamines inhibit α-synuclein fibril formation by oxidative ligation to the protein, selectively stabilizing the protofibril intermediate (preventing protofibril-to-fibril conversion), providing a mechanistic explanation for the dopaminergic selectivity of α-synuclein-associated neurotoxicity.","method":"In vitro fibril formation assay, compound library screen, biochemical characterization of dopamine–α-synuclein adducts","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution assay with chemical mechanism identified, >900 citations","pmids":["11701929"],"is_preprint":false},{"year":2002,"finding":"α-Synuclein is selectively and extensively phosphorylated at Ser129 in synucleinopathy lesions (PD, DLB, MSA); phosphorylation at Ser129 promotes fibril formation in vitro, identifying this modification as the dominant pathological post-translational modification.","method":"Mass spectrometry, phospho-specific antibody, in vitro fibril formation assay","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1 — MS identification of modification site plus in vitro functional validation, >1700 citations","pmids":["11813001"],"is_preprint":false},{"year":2002,"finding":"Mutant forms of α-synuclein associated with familial Parkinson's disease form annular protofibrils morphologically resembling pore-forming bacterial toxins, suggesting inappropriate membrane permeabilization as a pathogenic mechanism.","method":"Electron microscopy of recombinant protein assemblies, structural comparison","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — direct structural visualization of protofibril morphology, >1000 citations","pmids":["12124613"],"is_preprint":false},{"year":2003,"finding":"Triplication (four copies) of the SNCA locus causes early-onset Parkinson's disease with dementia, establishing that increased gene dosage of wild-type α-synuclein alone is sufficient to cause disease.","method":"Genomic dosage analysis, FISH, linkage analysis in large kindred","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 — genomic dosage determination in disease kindred, >3400 citations","pmids":["14593171"],"is_preprint":false},{"year":2004,"finding":"The E46K mutation in SNCA causes autosomal dominant Parkinson's disease and Lewy body dementia; Lewy bodies in affected individuals are immunoreactive to α-synuclein and ubiquitin, establishing E46K as a third causative SNCA point mutation.","method":"SNCA gene sequencing, neuropathological examination, family co-segregation analysis","journal":"Annals of neurology","confidence":"High","confidence_rationale":"Tier 2 — co-segregation with disease plus neuropathological confirmation, >2100 citations","pmids":["14755719"],"is_preprint":false},{"year":2004,"finding":"Duplication of the SNCA locus causes familial Parkinson's disease with a clinical phenotype resembling idiopathic PD (late onset, slow progression, no prominent dementia), contrasting with the more severe triplication phenotype—establishing a gene dosage–phenotype relationship.","method":"Semiquantitative PCR, FISH in peripheral leukocytes, clinical characterization","journal":"Lancet (London, England)","confidence":"High","confidence_rationale":"Tier 2 — genomic dosage determination with phenotypic correlation, >1600 citations","pmids":["15451224"],"is_preprint":false},{"year":2004,"finding":"Wild-type α-synuclein is normally degraded via the chaperone-mediated autophagy (CMA) pathway; pathogenic A53T and A30P mutants bind the lysosomal CMA receptor but act as uptake blockers, inhibiting their own degradation and that of other CMA substrates.","method":"Lysosomal uptake assay, receptor-binding assay, in vitro CMA reconstitution","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution of CMA pathway with mutagenesis comparison, >1600 citations","pmids":["15333840"],"is_preprint":false},{"year":2005,"finding":"Extracellular aggregated α-synuclein activates microglia in primary mesencephalic neuron-glia cultures; microglial activation enhances dopaminergic neurodegeneration through phagocytosis of α-synuclein and NADPH oxidase-dependent reactive oxygen species production.","method":"Primary mesencephalic culture, microglial phagocytosis assay, NADPH oxidase inhibition, dopaminergic neuron counting","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection in primary culture with pharmacological inhibition, >1000 citations","pmids":["15791003"],"is_preprint":false},{"year":2005,"finding":"α-Synuclein immunoreactive inclusions are present in neurons of the gastric submucosal Meissner plexus and myenteric Auerbach plexus in individuals staged for PD-related brain pathology, suggesting enteric nervous system involvement and a possible route for pathogen-induced α-synuclein misfolding spreading from gut to brain.","method":"Immunocytochemistry on cryosections and paraffin sections of gastric tissue, staging correlation","journal":"Neuroscience letters","confidence":"Medium","confidence_rationale":"Tier 3 — direct immunohistochemical localization correlated with brain staging, >1000 citations","pmids":["16330147"],"is_preprint":false},{"year":2006,"finding":"α-Synuclein accumulation in yeast causes an early block in ER-to-Golgi vesicular trafficking; a genome-wide screen identified Rab GTPase Ypt1p (mammalian Rab1) as the key modifier; overexpression of Rab1 protected against α-synuclein-induced dopaminergic neuron loss in C. elegans and rat neuron models.","method":"Yeast genome-wide modifier screen, ER-to-Golgi trafficking assay, C. elegans dopaminergic neuron counting, rat neuron culture","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 — genome-wide epistasis screen plus cross-species validation, >1100 citations","pmids":["16794039"],"is_preprint":false},{"year":2006,"finding":"Comprehensive inventory of α-synuclein modifications in Lewy bodies revealed that Ser129 phosphorylation is the predominant modification; ubiquitination occurs at Lys12, 21, and 23 and specific C-terminal truncations at Asp115, Asp119, Asn122, Tyr133, Asp135; ubiquitination appears secondary to phosphorylation and deposition.","method":"2D immunoblot, sandwich ELISA with modification-specific antibodies, tandem mass spectrometry","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — MS mapping of modification sites with multiple orthogonal methods, >1100 citations","pmids":["16847063"],"is_preprint":false},{"year":2008,"finding":"Patients homozygous for SNCA duplication show earlier onset and more severe cognitive impairment than heterozygotes, and biochemical analysis demonstrates that phosphorylated α-synuclein accumulates in the sarkosyl-insoluble urea-extracted fraction of brain, establishing a gene dosage–phosphorylation–aggregation relationship.","method":"Quantitative PCR for gene dosage, immunoblot of brain fractions, clinical characterization","journal":"Archives of neurology","confidence":"Medium","confidence_rationale":"Tier 2 — biochemical fractionation combined with genetic dosage determination","pmids":["18413475"],"is_preprint":false},{"year":2009,"finding":"α-Synuclein is transmitted from affected neurons to neighboring neurons and to engrafted neuronal precursor cells via endocytosis, forming Lewy-like inclusions in recipient cells; lysosomal dysfunction promotes accumulation of transmitted α-synuclein; recipient cells show apoptotic markers (nuclear fragmentation, caspase 3 activation).","method":"Co-culture transmission assay, endocytosis inhibition, transgenic mouse model grafting, caspase activity assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — cell-to-cell transmission demonstrated in vitro and in vivo with mechanistic dissection, >1100 citations","pmids":["19651612"],"is_preprint":false},{"year":2010,"finding":"α-Synuclein directly binds the SNARE protein synaptobrevin-2/VAMP2 and promotes SNARE-complex assembly; triple-knockout mice lacking all synucleins develop age-dependent neurological impairments with decreased SNARE-complex assembly, establishing α-synuclein as a non-classical chaperone for SNARE-complex assembly.","method":"Recombinant protein binding assay, in vitro SNARE-complex assembly assay, triple-knockout mouse phenotyping, brain biochemistry","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution of SNARE assembly plus genetic loss-of-function in mice, >1400 citations","pmids":["20798282"],"is_preprint":false},{"year":2011,"finding":"Endogenous α-synuclein isolated under non-denaturing conditions from neuronal and non-neuronal cell lines, brain tissue, and living human cells exists predominantly as a helically folded tetramer (~58 kDa); unlike recombinant monomers, native tetramers show α-helical structure without lipid addition, have greater lipid-binding capacity, and undergo little amyloid-like aggregation—suggesting that tetramer destabilization precedes pathological aggregation.","method":"Analytical ultracentrifugation, scanning transmission EM, in vivo crosslinking, CD spectroscopy, in vitro aggregation assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — multiple structural methods on endogenous protein, functional aggregation comparison, >1000 citations","pmids":["21841800"],"is_preprint":false},{"year":2011,"finding":"Functional loss of GD-linked glucocerebrosidase (GCase) in primary neurons and human iPSC-derived neurons causes lysosomal degradation impairment and α-synuclein accumulation; GCase substrate glucosylceramide (GlcCer) directly stabilizes soluble oligomeric α-synuclein intermediates in vitro; conversely, α-synuclein inhibits normal GCase lysosomal activity, forming a bidirectional pathogenic feedback loop.","method":"iPSC-derived neuron culture, in vitro GlcCer–α-synuclein aggregation assay, GCase activity assay in PD brain","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution plus iPSC neurons plus human PD brain validation, >1100 citations","pmids":["21700325"],"is_preprint":false},{"year":2013,"finding":"ABL1 tyrosine kinase is activated in PD brains and by lentiviral SNCA expression in mouse substantia nigra; lentiviral Abl expression increases SNCA levels; ABL1 inhibition with nilotinib decreases ABL1 activity and facilitates autophagic clearance of SNCA, with subcellular fractionation showing movement of SNCA from autophagic vacuoles to lysosomes.","method":"Lentiviral gene transfer in mice, subcellular fractionation, nilotinib treatment, transgenic mouse model","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 — bidirectional genetic manipulation (overexpression and inhibition) with subcellular fractionation","pmids":["23787811"],"is_preprint":false},{"year":2015,"finding":"Loss of GBA function in neuroblastoma cells and rat striatum leads to SNCA accumulation via inhibition of autophagy; this is mediated through PPP2A (protein phosphatase 2A) inactivation via Tyr307 phosphorylation, which suppresses BECN1 expression; PPP2A activation with C2-ceramide or rapamycin reverses GBA knockdown-induced SNCA accumulation.","method":"siRNA knockdown, glucocerebrosidase inhibition, PPP2A activity assay, pharmacological rescue in neuroblastoma cells and rat striatum","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway from GBA to PPP2A to autophagy to SNCA with pharmacological validation","pmids":["26378614"],"is_preprint":false},{"year":2015,"finding":"α-Synuclein assemblies of distinct conformational strains (oligomers, ribbons, fibrils) produce different histopathological and behavioral phenotypes after brain injection in rats; fibrils are the major toxic strain causing progressive motor impairment and cell death; ribbons produce a distinct phenotype with both PD and MSA traits; α-synuclein assemblies can cross the blood-brain barrier after intravenous injection and amplify in vivo.","method":"Intracerebral and intravenous injection of structurally defined α-synuclein assemblies, behavioral testing, neuropathology, in vivo amplification assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — systematic comparison of structurally defined strains with multiple functional readouts, >900 citations","pmids":["26061766"],"is_preprint":false},{"year":2018,"finding":"Targeted DNA methylation editing at SNCA intron 1 using a dCas9-DNMT3A lentiviral system causes fine-tuned downregulation of SNCA mRNA and protein in hiPSC-derived dopaminergic neurons from a PD patient with SNCA triplication; this reduction rescues disease-related cellular phenotypes including mitochondrial ROS production and reduced cell viability, establishing intron 1 DNA methylation as a regulator of SNCA transcription.","method":"CRISPR-dCas9-DNMT3A epigenome editing, hiPSC-derived dopaminergic neurons, qRT-PCR, Western blot, ROS assay, cell viability assay","journal":"Molecular therapy","confidence":"High","confidence_rationale":"Tier 1 — targeted epigenome editing with functional rescue in patient-derived neurons, multiple outcome measures","pmids":["30266652"],"is_preprint":false},{"year":2018,"finding":"CRISPR/Cas9n-mediated deletion of the endogenous SNCA gene in human embryonic stem cells confers dose-dependent resistance to α-synuclein preformed fibril (PFF)-induced Lewy-like pathology (pS129-αSyn aggregates) in mDA neurons, demonstrating that endogenous SNCA is required for seeded aggregation.","method":"CRISPR/Cas9n gene editing, hESC differentiation to mDA neurons, PFF seeding assay, phospho-α-synuclein immunofluorescence","journal":"The European journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — clean allele-dosage genetic deletion with defined seeding phenotype","pmids":["30472757"],"is_preprint":false},{"year":2021,"finding":"The novel SNCA A30G mutation causes familial PD; biophysical characterization shows A30G has a local effect on the intrinsically disordered structure of α-synuclein, slightly perturbs membrane binding, and promotes fibril formation in vitro.","method":"Whole exome sequencing, haplotype analysis, NMR/biophysical characterization of recombinant A30G αSyn, fibril formation assay","journal":"Movement disorders","confidence":"Medium","confidence_rationale":"Tier 1 — biophysical characterization of mutant protein with multiple methods; single lab","pmids":["33617693"],"is_preprint":false},{"year":2021,"finding":"Piperine (PIP) promotes autophagy flux via P2RX4 activation in SNCA-overexpression PD models; tandem mass tag proteomics identified P2RX4 as the key mediator; PIP enhanced autophagosome-lysosome membrane fusion and degradation of pathological SNCA in SK-N-SH cells and Thy1-SNCA transgenic mice, attenuating olfactory and motor deficits.","method":"TMT proteomics, autophagy flux assay (mRFP-GFP-LC3), transgenic mouse behavioral testing, siRNA knockdown of P2RX4","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 — proteomics-identified target validated by genetic knockdown and in vivo rescue","pmids":["34092198"],"is_preprint":false},{"year":2021,"finding":"SNCA triplication midbrain organoids derived from patient iPSCs exhibit elevated α-synuclein levels and age-dependent accumulation of oligomeric and phosphorylated α-synuclein in both neurons and glial cells, correlating with selective reduction in dopaminergic neuron numbers, establishing a 3D model of synucleinopathy.","method":"iPSC-derived midbrain organoids, CRISPR isogenic correction, phospho-α-synuclein immunofluorescence, dopaminergic neuron quantification","journal":"Brain communications","confidence":"Medium","confidence_rationale":"Tier 2 — isogenic CRISPR-corrected control with longitudinal organoid characterization","pmids":["34632384"],"is_preprint":false},{"year":2022,"finding":"Recombinant human pro-CTSD (cathepsin D) is endocytosed by neuronal cells, targeted to lysosomes, and matured to active protease; application to iPSC-derived dopaminergic neurons from PD patients with SNCA A53T mutation reduces insoluble SNCA; in ctsd-knockout mouse neurons and brain, rHsCTSD decreases pathological SNCA conformers and restores endo-lysosomal and autophagy function, establishing CTSD as a critical lysosomal protease for SNCA clearance.","method":"Enzyme replacement in iPSC-derived neurons and ctsd-KO mice, SIM, immunofluorescence, Western blot fractionation, lysosomal targeting assay","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 2 — genetic KO model plus enzyme replacement in patient-derived neurons and mouse brain, multiple orthogonal readouts","pmids":["35287553"],"is_preprint":false},{"year":2022,"finding":"Macroautophagy and CMA are the primary degradation pathways for endogenous oligodendroglial SNCA and TPPP/p25A; TPPP/p25A contains a KFERQ-like motif enabling CMA degradation; in MSA-like settings with PFF seeding, PFF treatment impairs autophagic flux, TPPP/p25A inhibits macroautophagy, and CMA is upregulated to compensate; augmenting CMA or macroautophagy accelerates removal of pathological SNCA assemblies.","method":"siRNA knockdown of ATG5/LAMP2A, pharmacological modulation (rapamycin, AR7, 3-MA), lysosomal CMA assay with rat brain lysosomes, PFF seeding in oligodendroglial cells","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 — multiple pathway manipulations with defined readouts in cellular and cell-free systems","pmids":["35000546"],"is_preprint":false},{"year":2023,"finding":"A 21-nucleotide duplication in SNCA (inserting MAAAEKT after residue 22, producing a 147-aa protein) causes juvenile-onset synucleinopathy; cryo-EM of sarkosyl-insoluble filaments from patient brain revealed a novel JOS α-synuclein fold (residues 36–100 as compact core, two disconnected density islands of mixed sequences, non-proteinaceous cofactor between core and island A) distinct from Lewy body disease and MSA folds; in vitro assembly of recombinant proteins yielded structures distinct from JOS filaments.","method":"Cryo-EM structure determination, genetic sequencing, in vitro fibril assembly, MS","journal":"Acta neuropathologica","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structure of patient-derived filaments with in vitro validation","pmids":["36847833"],"is_preprint":false},{"year":2017,"finding":"Blood RNA profiling of a SNCA gene duplication (PARK4) family revealed that CPLX1 (complexin 1) mRNA is inversely correlated with SNCA levels; SNCA gain of function impairs stimulus-triggered platelet degranulation; SNCA and CPLX1 mRNAs show inverse mutual regulation, and a CPLX1 3'-UTR SNP is significantly associated with PD risk.","method":"RNA-seq profiling of blood, platelet degranulation assay, qRT-PCR validation, genetic association analysis","journal":"Disease models & mechanisms","confidence":"Medium","confidence_rationale":"Tier 2 — functional platelet assay combined with transcriptomic and genetic evidence in PARK4 kindred","pmids":["28108469"],"is_preprint":false},{"year":2019,"finding":"SNCA multiplication (triplication) exacerbates neuronal nuclear aging: hiPSC-derived dopaminergic neurons from SNCA triplication patients show advanced aging signatures (altered heterochromatin, nuclear envelope markers, DNA damage, global DNA methylation) at juvenile stage; aged SNCA triplication neurons exhibit more α-synuclein aggregates per cell versus isogenic controls.","method":"hiPSC-derived neuron aging model (serial passaging of NPCs), immunofluorescence for heterochromatin/nuclear envelope markers, DNA damage assay, global DNA methylation analysis","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — isogenic hiPSC comparison with multiple nuclear aging markers","pmids":["30304516"],"is_preprint":false}],"current_model":"SNCA encodes α-synuclein, a natively unfolded (or physiologically helically folded tetrameric) presynaptic protein that normally functions as a non-classical chaperone promoting SNARE-complex assembly via direct binding to synaptobrevin-2/VAMP2; it is degraded primarily through chaperone-mediated autophagy and the autophagy-lysosome pathway (with CTSD as a key lysosomal protease and GCase/GlcCer regulating lysosomal function in a bidirectional loop with α-synuclein); pathogenic point mutations (A53T, A30P, E46K, A30G), gene duplications, or triplications cause α-synuclein to misfold, accumulate as phospho-Ser129 species, form strain-specific amyloid filament structures that block ER-to-Golgi trafficking, activate microglia via NADPH oxidase, propagate between cells via endocytosis, and deposit as Lewy bodies—with dopamine oxidative ligation to α-synuclein stabilizing toxic protofibrillar intermediates and chaperones (Hsp70) suppressing dopaminergic neurodegeneration."},"narrative":{"teleology":[{"year":1993,"claim":"Identification of SNCA as the precursor of NAC, a component of AD amyloid, established its amyloidogenic potential and provided the molecular clone needed for all subsequent functional studies.","evidence":"cDNA cloning, amino acid sequencing, immunoblot, and secondary structure prediction from human brain","pmids":["8248242"],"confidence":"High","gaps":["Physiological function completely unknown","Relationship to neurodegeneration beyond AD amyloid association unclear"]},{"year":1996,"claim":"Biophysical characterization revealed α-synuclein is natively unfolded, lacking stable secondary structure or a hydrophobic core, which explained its unusual biochemical behavior and raised questions about how a disordered protein could form ordered aggregates.","evidence":"Analytical ultracentrifugation, CD, FTIR, gel filtration on recombinant protein","pmids":["8901511"],"confidence":"High","gaps":["Whether unfolded state is the sole physiological conformation (later challenged by tetramer hypothesis)","Mechanism by which an unfolded protein nucleates amyloid not addressed"]},{"year":1997,"claim":"The A53T mutation co-segregating with autosomal dominant PD in multiple families, combined with α-synuclein immunoreactivity in all Lewy bodies, established SNCA as the first PD gene and its protein as the principal Lewy body component.","evidence":"Linkage analysis and sequencing in Italian/Greek PD families; double-label immunohistochemistry on sporadic PD brain","pmids":["9197268","9547168"],"confidence":"High","gaps":["Mechanism by which A53T causes disease not yet known","Whether wild-type α-synuclein contributes to sporadic PD unresolved"]},{"year":1998,"claim":"Discovery of A30P as a second causative SNCA mutation confirmed that the gene is a bona fide PD locus and that multiple positions in α-synuclein's N-terminal repeat region are vulnerable to pathogenic substitution.","evidence":"Mutation screening and co-segregation in a German PD family","pmids":["9462735"],"confidence":"High","gaps":["Structural basis for how A30P differs mechanistically from A53T unknown"]},{"year":2001,"claim":"Two discoveries resolved key aspects of α-synuclein toxicity: dopamine oxidative ligation stabilizes toxic protofibrillar intermediates (explaining dopaminergic selectivity), and Hsp70 chaperone activity suppresses α-synuclein-induced dopaminergic neuron loss (identifying the protein quality control axis as protective).","evidence":"In vitro fibril formation with dopamine-adduct characterization; transgenic Drosophila with Hsp70 co-expression and genetic epistasis","pmids":["11701929","11823645"],"confidence":"High","gaps":["Whether dopamine-stabilized protofibrils are the toxic species in vivo unproven","Hsp70 mechanism of action on α-synuclein (refolding vs disaggregation vs degradation) not defined"]},{"year":2002,"claim":"Identification of Ser129 phosphorylation as the dominant pathological modification and visualization of annular protofibrillar structures for mutant α-synuclein established a post-translational and structural framework for synucleinopathy.","evidence":"Mass spectrometry and phospho-specific antibodies on disease brain; electron microscopy of recombinant mutant assemblies","pmids":["11813001","12124613"],"confidence":"High","gaps":["Whether Ser129 phosphorylation is causally required for aggregation or merely correlative in vivo","Identity of the kinase(s) responsible in vivo not resolved"]},{"year":2003,"claim":"SNCA locus triplication causing early-onset PD with dementia proved that increased dosage of wild-type α-synuclein alone suffices for disease, fundamentally reframing PD pathogenesis as a gene-dose problem.","evidence":"Genomic dosage analysis and FISH in a large Iowa kindred","pmids":["14593171"],"confidence":"High","gaps":["Threshold of expression increase needed for pathogenesis not defined","Mechanism linking overexpression to selective dopaminergic vulnerability unclear"]},{"year":2004,"claim":"Identification of E46K as a third causative mutation and SNCA duplication as a milder dose-dependent PD cause, together with discovery that wild-type α-synuclein is cleared via CMA while mutants block the pathway, connected genetic dose and mutant-specific toxicity to the lysosomal degradation axis.","evidence":"E46K family co-segregation with neuropathology; FISH for duplication; in vitro CMA reconstitution with lysosomal uptake and receptor-binding assays","pmids":["14755719","15451224","15333840"],"confidence":"High","gaps":["Whether CMA blockade by mutant α-synuclein is sufficient for disease in vivo","Relative contribution of CMA versus macroautophagy to α-synuclein clearance in neurons not quantified"]},{"year":2006,"claim":"A yeast genome-wide screen identified Rab1-sensitive ER-to-Golgi trafficking as the primary pathway blocked by α-synuclein accumulation, validated across C. elegans and rat neurons, establishing vesicular trafficking disruption as a core cytotoxic mechanism.","evidence":"Genome-wide overexpression/deletion screen in yeast; ER-to-Golgi assay; cross-species rescue experiments","pmids":["16794039"],"confidence":"High","gaps":["Whether ER-to-Golgi block is a direct stoichiometric effect of α-synuclein on vesicle fusion or indirect","Mammalian Rab GTPases other than Rab1 that may compensate not explored"]},{"year":2009,"claim":"Demonstration that α-synuclein transmits from affected to naïve neurons via endocytosis and seeds Lewy-like inclusions in recipient cells established prion-like propagation as a disease mechanism.","evidence":"Co-culture transmission assay with endocytosis inhibition; grafting into transgenic mouse brain; caspase 3 activation in recipient cells","pmids":["19651612"],"confidence":"High","gaps":["Receptor or uptake mechanism for α-synuclein entry into recipient cells not identified","Whether propagation drives disease progression in human PD unproven"]},{"year":2010,"claim":"Reconstitution of α-synuclein's physiological function showed it directly binds VAMP2 and promotes SNARE-complex assembly, with triple-synuclein knockout mice developing age-dependent neurological impairment, establishing α-synuclein as a presynaptic SNARE chaperone.","evidence":"Recombinant protein binding and SNARE assembly reconstitution; triple-knockout mouse phenotyping with brain biochemistry","pmids":["20798282"],"confidence":"High","gaps":["Redundancy among synuclein family members for SNARE chaperoning not fully dissected","Whether loss of SNARE chaperone function contributes to PD pathogenesis distinct from gain-of-toxic-function"]},{"year":2011,"claim":"Two parallel advances reshaped the field: endogenous α-synuclein exists as a helically folded tetramer resistant to aggregation (challenging the unfolded monomer paradigm), and GCase loss creates a bidirectional pathogenic loop where glucosylceramide stabilizes α-synuclein oligomers while α-synuclein inhibits GCase activity.","evidence":"Analytical ultracentrifugation and EM on endogenous protein; iPSC-derived neurons and in vitro GlcCer–α-synuclein aggregation assay with GCase activity in PD brain","pmids":["21841800","21700325"],"confidence":"High","gaps":["Tetramer versus monomer debate not fully resolved—conditions of native isolation remain debated","Quantitative contribution of GCase–α-synuclein loop to sporadic PD unknown"]},{"year":2015,"claim":"Injection of structurally defined α-synuclein strains (oligomers, ribbons, fibrils) into rat brain produced distinct pathological and behavioral phenotypes, establishing the prion strain concept for synucleinopathies and demonstrating that fibrils cross the blood-brain barrier.","evidence":"Intracerebral and intravenous injection of characterized assemblies; behavioral testing and neuropathology","pmids":["26061766"],"confidence":"High","gaps":["Whether strain-specific folds found in animal models correspond to human disease subtypes not confirmed","Mechanism of blood-brain barrier crossing unknown"]},{"year":2018,"claim":"Epigenome editing at SNCA intron 1 using dCas9-DNMT3A rescued disease phenotypes in triplication patient-derived neurons, and CRISPR deletion of SNCA abolished PFF-seeded aggregation, together establishing intron 1 methylation as a transcriptional regulator and endogenous α-synuclein as required for seeded pathology.","evidence":"dCas9-DNMT3A lentiviral system in triplication iPSC-DA neurons; CRISPR/Cas9n SNCA knockout in hESC-derived mDA neurons with PFF seeding","pmids":["30266652","30472757"],"confidence":"High","gaps":["Therapeutic window for methylation-based SNCA reduction not defined","Whether complete SNCA elimination has long-term detrimental effects on synaptic function"]},{"year":2022,"claim":"Recombinant cathepsin D replacement in iPSC-derived A53T neurons and ctsd-KO mice cleared pathological α-synuclein conformers and restored endo-lysosomal function, establishing CTSD as the critical lysosomal protease for α-synuclein degradation.","evidence":"Enzyme replacement therapy in patient iPSC-DA neurons and ctsd-KO mouse brain; SIM imaging, Western blot fractionation, lysosomal targeting assays","pmids":["35287553"],"confidence":"High","gaps":["Whether CTSD is rate-limiting in sporadic PD lysosomes not established","Delivery of recombinant CTSD to human brain not demonstrated"]},{"year":2023,"claim":"Cryo-EM of brain-derived filaments from a patient with a 21-nucleotide SNCA insertion revealed a novel α-synuclein fold distinct from Lewy body and MSA folds, with a non-proteinaceous cofactor, strengthening the concept that distinct structural polymorphs underlie distinct synucleinopathies.","evidence":"Cryo-EM structure determination of sarkosyl-insoluble filaments from JOS patient brain; comparison with in vitro assembled filaments","pmids":["36847833"],"confidence":"High","gaps":["Identity of the non-proteinaceous cofactor unknown","Whether the JOS fold can be reproduced in vitro with the correct cofactor not achieved","Structural basis for strain-specific toxicity not resolved"]},{"year":null,"claim":"Key unresolved questions include the identity of the physiological α-synuclein conformation in vivo (tetramer vs. monomer equilibrium), the receptor mediating cell-to-cell propagation, the structural determinants of strain-specific toxicity, and whether loss of SNARE chaperone function contributes to disease independently of toxic aggregation.","evidence":"","pmids":[],"confidence":"High","gaps":["Native quaternary state in living neurons remains debated","No receptor for α-synuclein uptake during propagation identified","Relative contribution of loss-of-function versus gain-of-toxic-function to PD not quantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0044183","term_label":"protein folding chaperone","supporting_discovery_ids":[23]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[6,24]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[23]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,1]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[6,19]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[16,34,35]}],"pathway":[{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[23,37]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[16,26,27,32,34,35]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,7,13,14,15]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[19,22]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[22]}],"complexes":["SNARE complex (as chaperone, not stable subunit)"],"partners":["VAMP2","GBA","CTSD","HSPA1A","CPLX1","RAB1A"],"other_free_text":[]},"mechanistic_narrative":"α-Synuclein (SNCA) is a presynaptic, natively unfolded protein that functions as a non-classical chaperone promoting SNARE-complex assembly through direct binding to synaptobrevin-2/VAMP2, and whose misfolding and aggregation into phospho-Ser129-positive amyloid filaments underlies Parkinson's disease and related synucleinopathies [PMID:20798282, PMID:11813001]. Pathogenic point mutations (A53T, A30P, E46K, A30G), gene duplications, or triplications cause dose-dependent dopaminergic neurodegeneration by promoting fibril formation, blocking ER-to-Golgi trafficking, activating microglial NADPH oxidase, and propagating between neurons via endocytosis [PMID:9197268, PMID:16794039, PMID:15791003, PMID:19651612, PMID:14593171]. α-Synuclein is normally cleared through chaperone-mediated autophagy and the autophagy–lysosome pathway, where cathepsin D serves as a critical lysosomal protease and a bidirectional feedback loop with glucocerebrosidase/glucosylceramide modulates its lysosomal turnover [PMID:15333840, PMID:35287553, PMID:21700325]. Dopamine oxidatively ligates to α-synuclein and stabilizes toxic protofibrillar intermediates, providing a molecular basis for the selective vulnerability of dopaminergic neurons, while molecular chaperones such as Hsp70 suppress α-synuclein-mediated neurodegeneration [PMID:11701929, PMID:11823645]."},"prefetch_data":{"uniprot":{"accession":"P37840","full_name":"Alpha-synuclein","aliases":["Non-A beta component of AD amyloid","Non-A4 component of amyloid precursor","NACP"],"length_aa":140,"mass_kda":14.5,"function":"Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release (PubMed:20798282, PubMed:26442590, PubMed:28288128, PubMed:30404828). Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores (PubMed:28288128, PubMed:30404828). Mechanistically, acts by increasing local Ca(2+) release from microdomains which is essential for the enhancement of ATP-induced exocytosis (PubMed:30404828). Also acts as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs (Soluble NSF Attachment Protein REceptors) at presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5 (PubMed:20798282). This chaperone activity is important to sustain normal SNARE-complex assembly during aging (PubMed:20798282). Also plays a role in the regulation of the dopamine neurotransmission by associating with the dopamine transporter (DAT1) and thereby modulating its activity (PubMed:26442590)","subcellular_location":"Cytoplasm; Membrane; Nucleus; Synapse; Secreted; Cell projection, axon","url":"https://www.uniprot.org/uniprotkb/P37840/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SNCA","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SNCA","total_profiled":1310},"omim":[{"mim_id":"621516","title":"DIFFERENTIALLY EXPRESSED IN FDCP 8, MOUSE, HOMOLOG OF; DEF8","url":"https://www.omim.org/entry/621516"},{"mim_id":"621213","title":"FAMILY WITH SEQUENCE SIMILARITY 171, MEMBER A2; FAM171A2","url":"https://www.omim.org/entry/621213"},{"mim_id":"620636","title":"NEURODEGENERATION, CHILDHOOD-ONSET, WITH CEREBELLAR ATAXIA AND COGNITIVE DECLINE; CONDCAC","url":"https://www.omim.org/entry/620636"},{"mim_id":"620215","title":"MEMBRANE INTEGRAL NOTCH2-ASSOCIATED RECEPTOR 2; MINAR2","url":"https://www.omim.org/entry/620215"},{"mim_id":"620048","title":"RETENTION IN ENDOPLASMIC RETICULUM SORTING RECEPTOR 1; RER1","url":"https://www.omim.org/entry/620048"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":257.8},{"tissue":"brain","ntpm":263.1}],"url":"https://www.proteinatlas.org/search/SNCA"},"hgnc":{"alias_symbol":["NACP","PD1"],"prev_symbol":["PARK1","PARK4"]},"alphafold":{"accession":"P37840","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P37840","model_url":"https://alphafold.ebi.ac.uk/files/AF-P37840-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P37840-F1-predicted_aligned_error_v6.png","plddt_mean":75.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SNCA","jax_strain_url":"https://www.jax.org/strain/search?query=SNCA"},"sequence":{"accession":"P37840","fasta_url":"https://rest.uniprot.org/uniprotkb/P37840.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P37840/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P37840"}},"corpus_meta":[{"pmid":"25428505","id":"PMC_25428505","title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/25428505","citation_count":5424,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18173375","id":"PMC_18173375","title":"PD-1 and its ligands in tolerance and immunity.","date":"2008","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18173375","citation_count":4338,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27433843","id":"PMC_27433843","title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.","date":"2016","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27433843","citation_count":2538,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20636820","id":"PMC_20636820","title":"The PD-1 pathway in tolerance and autoimmunity.","date":"2010","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/20636820","citation_count":1847,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29658848","id":"PMC_29658848","title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.","date":"2018","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29658848","citation_count":1605,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28990585","id":"PMC_28990585","title":"The diverse functions of the PD1 inhibitory pathway.","date":"2017","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28990585","citation_count":1508,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8901511","id":"PMC_8901511","title":"NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded.","date":"1996","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8901511","citation_count":1293,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25534622","id":"PMC_25534622","title":"Clinical blockade of PD1 and LAG3--potential mechanisms of action.","date":"2015","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25534622","citation_count":507,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32948597","id":"PMC_32948597","title":"Revisiting the PD-1 pathway.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/32948597","citation_count":412,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20506312","id":"PMC_20506312","title":"Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/20506312","citation_count":397,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17433872","id":"PMC_17433872","title":"PD-1 and its ligands in T-cell immunity.","date":"2007","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17433872","citation_count":347,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32036071","id":"PMC_32036071","title":"Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.","date":"2020","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32036071","citation_count":343,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9547168","id":"PMC_9547168","title":"NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease.","date":"1997","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/9547168","citation_count":283,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29643229","id":"PMC_29643229","title":"T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.","date":"2018","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29643229","citation_count":257,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26945088","id":"PMC_26945088","title":"Genetic and Epigenetic Regulation of PD-1 Expression.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26945088","citation_count":194,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25178429","id":"PMC_25178429","title":"APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.","date":"2014","source":"JAMA neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25178429","citation_count":170,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26350119","id":"PMC_26350119","title":"Autosomal dominant Parkinson's disease caused by SNCA duplications.","date":"2015","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/26350119","citation_count":163,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28929192","id":"PMC_28929192","title":"Role of PD-1 in Immunity and Diseases.","date":"2017","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28929192","citation_count":162,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28000302","id":"PMC_28000302","title":"PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'.","date":"2016","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/28000302","citation_count":158,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30357936","id":"PMC_30357936","title":"Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review.","date":"2018","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/30357936","citation_count":153,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35228677","id":"PMC_35228677","title":"Biomarkers of response to PD-1 pathway blockade.","date":"2022","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35228677","citation_count":150,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30266652","id":"PMC_30266652","title":"Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD.","date":"2018","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30266652","citation_count":150,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8546207","id":"PMC_8546207","title":"Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease.","date":"1996","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8546207","citation_count":146,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26162965","id":"PMC_26162965","title":"New immunotherapies targeting the PD-1 pathway.","date":"2015","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26162965","citation_count":145,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25810391","id":"PMC_25810391","title":"NF-κB regulates PD-1 expression in macrophages.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25810391","citation_count":144,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34368780","id":"PMC_34368780","title":"PAK4 inhibition improves PD-1 blockade immunotherapy.","date":"2019","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34368780","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27080380","id":"PMC_27080380","title":"The Parkinson Disease gene SNCA: Evolutionary and structural insights with pathological implication.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27080380","citation_count":123,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28642997","id":"PMC_28642997","title":"PD-1 and cancer: molecular mechanisms and polymorphisms.","date":"2017","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/28642997","citation_count":120,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26317459","id":"PMC_26317459","title":"PD-1 Blockers.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26317459","citation_count":120,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38867043","id":"PMC_38867043","title":"Obesity induces PD-1 on macrophages to suppress anti-tumour immunity.","date":"2024","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/38867043","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29352857","id":"PMC_29352857","title":"Combining chemotherapy with PD-1 blockade in NSCLC.","date":"2018","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/29352857","citation_count":113,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18413475","id":"PMC_18413475","title":"Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia.","date":"2008","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/18413475","citation_count":109,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26378614","id":"PMC_26378614","title":"GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A.","date":"2015","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/26378614","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9299413","id":"PMC_9299413","title":"NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation.","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9299413","citation_count":101,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28314785","id":"PMC_28314785","title":"Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28314785","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24975127","id":"PMC_24975127","title":"PD-1 regulates extrathymic regulatory T-cell differentiation.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24975127","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31817953","id":"PMC_31817953","title":"Basis of PD1/PD-L1 Therapies.","date":"2019","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31817953","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23582509","id":"PMC_23582509","title":"Manipulating the PD-1 pathway to improve immunity.","date":"2013","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23582509","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33617693","id":"PMC_33617693","title":"A Novel SNCA A30G Mutation Causes Familial Parkinson's Disease.","date":"2021","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/33617693","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33229411","id":"PMC_33229411","title":"KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.","date":"2020","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/33229411","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29096940","id":"PMC_29096940","title":"Anti-PD1/PDL1 induced psoriasis.","date":"2017","source":"Current problems in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29096940","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7601450","id":"PMC_7601450","title":"The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7601450","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30165419","id":"PMC_30165419","title":"Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types.","date":"2018","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30165419","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24326201","id":"PMC_24326201","title":"Hypomethylation of SNCA in blood of patients with sporadic Parkinson's disease.","date":"2013","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24326201","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30396745","id":"PMC_30396745","title":"PD-1 immunobiology in systemic lupus erythematosus.","date":"2018","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/30396745","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20433954","id":"PMC_20433954","title":"PD-1, gender, and autoimmunity.","date":"2010","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/20433954","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21391235","id":"PMC_21391235","title":"Independent and joint effects of the MAPT and SNCA genes in Parkinson disease.","date":"2011","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21391235","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37208329","id":"PMC_37208329","title":"ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37208329","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32680952","id":"PMC_32680952","title":"Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding.","date":"2020","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32680952","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25098286","id":"PMC_25098286","title":"PD-1 as an immune modulatory receptor.","date":"2014","source":"Cancer journal (Sudbury, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/25098286","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10899435","id":"PMC_10899435","title":"Properties of NACP/alpha-synuclein and its role in Alzheimer's disease.","date":"2000","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/10899435","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36847833","id":"PMC_36847833","title":"New SNCA mutation and structures of α-synuclein filaments from juvenile-onset synucleinopathy.","date":"2023","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/36847833","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24768741","id":"PMC_24768741","title":"Genetic variants and animal models in SNCA and Parkinson disease.","date":"2014","source":"Ageing research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/24768741","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34092198","id":"PMC_34092198","title":"Piperine promotes autophagy flux by P2RX4 activation in SNCA/α-synuclein-induced Parkinson disease model.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/34092198","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30472757","id":"PMC_30472757","title":"Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene.","date":"2018","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30472757","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36007524","id":"PMC_36007524","title":"Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade.","date":"2022","source":"Med (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/36007524","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35287553","id":"PMC_35287553","title":"Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/35287553","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27717584","id":"PMC_27717584","title":"Parkinson's disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus.","date":"2016","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/27717584","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25554495","id":"PMC_25554495","title":"Link between the SNCA gene and parkinsonism.","date":"2014","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/25554495","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28445713","id":"PMC_28445713","title":"Deregulation of α-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA.","date":"2017","source":"Progress in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28445713","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34632384","id":"PMC_34632384","title":"Midbrain organoids with an SNCA gene triplication model key features of synucleinopathy.","date":"2021","source":"Brain communications","url":"https://pubmed.ncbi.nlm.nih.gov/34632384","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15670652","id":"PMC_15670652","title":"Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease.","date":"2004","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/15670652","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30146727","id":"PMC_30146727","title":"A comprehensive analysis of SNCA-related genetic risk in sporadic parkinson disease.","date":"2018","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30146727","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10640638","id":"PMC_10640638","title":"Plaque-associated alpha-synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein.","date":"2000","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10640638","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25625924","id":"PMC_25625924","title":"PD-1 and PD-L1 antibodies for melanoma.","date":"2014","source":"Human vaccines & immunotherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25625924","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31495293","id":"PMC_31495293","title":"The impact of corticosteroid use during anti-PD1 treatment.","date":"2019","source":"Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners","url":"https://pubmed.ncbi.nlm.nih.gov/31495293","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38401888","id":"PMC_38401888","title":"PD-1 regulation in immune homeostasis and immunotherapy.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38401888","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23787811","id":"PMC_23787811","title":"Tyrosine kinase inhibition facilitates autophagic SNCA/α-synuclein clearance.","date":"2013","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/23787811","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27685250","id":"PMC_27685250","title":"DNA methylation changes at SNCA intron 1 in patients with dementia with Lewy bodies.","date":"2016","source":"Psychiatry and clinical neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/27685250","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29300342","id":"PMC_29300342","title":"SNCA Is a Functionally Low-Expressed Gene in Lung Adenocarcinoma.","date":"2018","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/29300342","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28781905","id":"PMC_28781905","title":"Genetic Variants in SNCA and the Risk of Sporadic Parkinson's Disease and Clinical Outcomes: A Review.","date":"2017","source":"Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/28781905","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30536337","id":"PMC_30536337","title":"LncRNA-UCA1 promotes PD development by upregulating SNCA.","date":"2018","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30536337","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35596947","id":"PMC_35596947","title":"Parkinson's Disease Derived Exosomes Aggravate Neuropathology in SNCA*A53T Mice.","date":"2022","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35596947","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32492969","id":"PMC_32492969","title":"PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32492969","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31417907","id":"PMC_31417907","title":"Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies.","date":"2019","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31417907","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30563566","id":"PMC_30563566","title":"Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy.","date":"2018","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30563566","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22104010","id":"PMC_22104010","title":"SNCA and MAPT genes: Independent and joint effects in Parkinson disease in the Italian population.","date":"2011","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/22104010","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33905818","id":"PMC_33905818","title":"PD-1 signaling pathway in sepsis: Does it have a future?","date":"2021","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/33905818","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24504486","id":"PMC_24504486","title":"Potential of new therapies like anti-PD1 in kidney cancer.","date":"2014","source":"Current treatment options in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24504486","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28739716","id":"PMC_28739716","title":"Clinical Significance of PD1 and PDL1 in Human Breast Cancer.","date":"2017","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28739716","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37653141","id":"PMC_37653141","title":"Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade.","date":"2023","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37653141","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27567856","id":"PMC_27567856","title":"Elevated mRNA Expression and Low Methylation of SNCA in Japanese Alzheimer's Disease Subjects.","date":"2016","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/27567856","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34170628","id":"PMC_34170628","title":"The PD-1 Interactome.","date":"2021","source":"Advanced biology","url":"https://pubmed.ncbi.nlm.nih.gov/34170628","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29928688","id":"PMC_29928688","title":"Genetic fine-mapping of the Iowan SNCA gene triplication in a patient with Parkinson's disease.","date":"2018","source":"NPJ Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/29928688","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28643044","id":"PMC_28643044","title":"PD-1 signaling and inhibition in AML and MDS.","date":"2017","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/28643044","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33738533","id":"PMC_33738533","title":"Transcriptional and epigenetic regulation of PD-1 expression.","date":"2021","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/33738533","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28912094","id":"PMC_28912094","title":"Selection of PD1/PD-L1 X-Aptamers.","date":"2017","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/28912094","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25656566","id":"PMC_25656566","title":"Alpha-synuclein (SNCA) polymorphisms and susceptibility to Parkinson's disease: a meta-analysis.","date":"2015","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25656566","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32154657","id":"PMC_32154657","title":"miR-30b protects nigrostriatal dopaminergic neurons from MPP(+)-induced neurotoxicity via SNCA.","date":"2020","source":"Brain and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/32154657","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9555070","id":"PMC_9555070","title":"Changes in presynaptic protein NACP/alpha-synuclein in an ischemic gerbil hippocampus.","date":"1998","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/9555070","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35640711","id":"PMC_35640711","title":"Strategies for developing PD-1 inhibitors and future directions.","date":"2022","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35640711","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34729183","id":"PMC_34729183","title":"SLAMF8 expression predicts the efficacy of anti-PD1 immunotherapy in gastrointestinal cancers.","date":"2021","source":"Clinical & translational immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34729183","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34799977","id":"PMC_34799977","title":"α-Synuclein antisense transcript SNCA-AS1 regulates synapses- and aging-related genes suggesting its implication in Parkinson's disease.","date":"2021","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/34799977","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30304516","id":"PMC_30304516","title":"Multiplication of the SNCA locus exacerbates neuronal nuclear aging.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30304516","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35000546","id":"PMC_35000546","title":"Autophagy mediates the clearance of oligodendroglial SNCA/alpha-synuclein and TPPP/p25A in multiple system atrophy models.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/35000546","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21899511","id":"PMC_21899511","title":"PD-1 and autoimmunity.","date":"2011","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21899511","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33676416","id":"PMC_33676416","title":"PD-1 immunobiology in glomerulonephritis and renal cell carcinoma.","date":"2021","source":"BMC nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/33676416","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30927248","id":"PMC_30927248","title":"Beyond PD-1 Immunotherapy in Malignant Melanoma.","date":"2019","source":"Dermatology and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30927248","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31178336","id":"PMC_31178336","title":"Small fiber neuropathy and phosphorylated alpha-synuclein in the skin of E46K-SNCA mutation carriers.","date":"2019","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/31178336","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28108469","id":"PMC_28108469","title":"Blood RNA biomarkers in prodromal PARK4 and rapid eye movement sleep behavior disorder show role of complexin 1 loss for risk of Parkinson's disease.","date":"2017","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/28108469","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9197268","id":"PMC_9197268","title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.","date":"1997","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9197268","citation_count":6605,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14593171","id":"PMC_14593171","title":"alpha-Synuclein locus triplication causes Parkinson's disease.","date":"2003","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/14593171","citation_count":3495,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9462735","id":"PMC_9462735","title":"Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.","date":"1998","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9462735","citation_count":3181,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20098416","id":"PMC_20098416","title":"PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1.","date":"2010","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20098416","citation_count":2356,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14755719","id":"PMC_14755719","title":"The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia.","date":"2004","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/14755719","citation_count":2183,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11813001","id":"PMC_11813001","title":"alpha-Synuclein is phosphorylated in synucleinopathy lesions.","date":"2002","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11813001","citation_count":1744,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15333840","id":"PMC_15333840","title":"Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.","date":"2004","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15333840","citation_count":1632,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15451224","id":"PMC_15451224","title":"Alpha-synuclein locus duplication as a cause of familial Parkinson's disease.","date":"2004","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15451224","citation_count":1632,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19915575","id":"PMC_19915575","title":"Genome-wide association study reveals genetic risk underlying Parkinson's disease.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19915575","citation_count":1562,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25064009","id":"PMC_25064009","title":"Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease.","date":"2014","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25064009","citation_count":1512,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20798282","id":"PMC_20798282","title":"Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.","date":"2010","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20798282","citation_count":1445,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24252804","id":"PMC_24252804","title":"The role of oxidative stress in Parkinson's disease.","date":"2013","source":"Journal of Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/24252804","citation_count":1396,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8248242","id":"PMC_8248242","title":"Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8248242","citation_count":1232,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19651612","id":"PMC_19651612","title":"Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19651612","citation_count":1185,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16847063","id":"PMC_16847063","title":"Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16847063","citation_count":1161,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30646912","id":"PMC_30646912","title":"Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.","date":"2019","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30646912","citation_count":1144,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21700325","id":"PMC_21700325","title":"Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.","date":"2011","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21700325","citation_count":1126,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16794039","id":"PMC_16794039","title":"Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models.","date":"2006","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/16794039","citation_count":1113,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19915576","id":"PMC_19915576","title":"Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19915576","citation_count":1077,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16330147","id":"PMC_16330147","title":"Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology.","date":"2005","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/16330147","citation_count":1051,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12124613","id":"PMC_12124613","title":"Neurodegenerative disease: amyloid pores from pathogenic mutations.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12124613","citation_count":1048,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21841800","id":"PMC_21841800","title":"α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21841800","citation_count":1030,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15791003","id":"PMC_15791003","title":"Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.","date":"2005","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/15791003","citation_count":1006,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11823645","id":"PMC_11823645","title":"Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.","date":"2001","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/11823645","citation_count":989,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11701929","id":"PMC_11701929","title":"Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.","date":"2001","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/11701929","citation_count":929,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26061766","id":"PMC_26061766","title":"α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26061766","citation_count":912,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46639,"output_tokens":4599,"usd":0.104451},"stage2":{"model":"claude-opus-4-6","input_tokens":8078,"output_tokens":3464,"usd":0.190485},"total_usd":0.707196,"stage1_batch_id":"msgbatch_011rkcQdVV1RaFq9XhcG6df6","stage2_batch_id":"msgbatch_01RzgrJafdF4EWHhj5mNi6dh","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":58420,"output_tokens":9295,"usd":0.157342},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":13154,"output_tokens":4167,"usd":0.254918}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"SNCA (NACP/alpha-synuclein) is a natively unfolded protein lacking significant secondary structure, hydrophobic core, or stable tertiary fold, existing as rapidly equilibrating extended conformers under physiological conditions.\",\n      \"method\": \"Circular dichroism, FTIR spectroscopy, ultraviolet spectroscopy, analytical ultracentrifugation, and size-exclusion chromatography\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal biophysical methods in a single study, foundational paper with >1200 citations\",\n      \"pmids\": [\"8901511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"SNCA (NACP) is a presynaptic protein that colocalizes with synaptophysin-immunoreactive structures (presynaptic terminals) in human brain and accumulates in dystrophic neuritic components of amyloid plaques in Alzheimer's disease.\",\n      \"method\": \"Semiquantitative immunoblotting and double-immunocytochemistry/laser scanning confocal microscopy\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization by confocal microscopy with functional context, foundational paper\",\n      \"pmids\": [\"8546207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"SNCA (NACP/alpha-synuclein) accumulates in Lewy bodies and degenerating neurites in Parkinson's disease brains, with all ubiquitin-immunoreactive Lewy bodies also being NACP-immunoreactive, indicating SNCA is a major component of Lewy bodies.\",\n      \"method\": \"Immunohistochemistry with anti-NACP and anti-ubiquitin antibodies on serial sections of sporadic PD brains\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization by immunohistochemistry, replicated across multiple PD cases, >280 citations\",\n      \"pmids\": [\"9547168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"SNCA (NACP) is loosely associated with the plasma membrane, the endomembrane system, and membranes of secretory alpha-granules in platelets; its expression is upregulated during phorbol ester-induced megakaryocytic differentiation of K562 cells while beta-synuclein is downregulated.\",\n      \"method\": \"Immunogold electron microscopy and immunoblotting of platelets and K562 cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct subcellular localization by immunogold EM with biochemical confirmation\",\n      \"pmids\": [\"9299413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"SNCA (NACP) undergoes pathological redistribution in hippocampal neurons following ischemia, with transient accumulation around cerebral blood vessels and development of unusual tubal and chain-like structures, suggesting SNCA participates in ischemic pathogenesis.\",\n      \"method\": \"Immunohistochemistry of gerbil hippocampus at multiple time points after ischemia\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single method, single model organism, no molecular mechanism defined\",\n      \"pmids\": [\"9555070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"SNCA (NACP/alpha-synuclein) accumulates abnormally at synapses of Alzheimer's disease patients along with APP, and abnormal transport, metabolism, or function of SNCA impairs synaptic function contributing to neurodegeneration.\",\n      \"method\": \"Review synthesizing immunocytochemical and biochemical evidence from multiple studies\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — review synthesis without new experimental data\",\n      \"pmids\": [\"10899435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SNCA gene duplication causes autosomal dominant Lewy body disease with dosage-dependent effects: homozygous duplication (4 copies) produces earlier onset and more severe cognitive impairment than heterozygous duplication (3 copies), and is associated with hyperaccumulation of phosphorylated alpha-synuclein in the sarkosyl-insoluble urea-extracted fraction of brain.\",\n      \"method\": \"Quantitative PCR for gene dosage, immunoblot analysis of brain fractions from autopsied patients\",\n      \"journal\": \"Archives of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical fractionation and gene dosage analysis in pathologically confirmed cases, demonstrates dose-response relationship\",\n      \"pmids\": [\"18413475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ABL1 tyrosine kinase is activated by SNCA overexpression in mouse substantia nigra (via phosphorylation), and in turn ABL1 activity increases SNCA levels; inhibition of ABL1 with Nilotinib facilitates autophagic clearance of SNCA by promoting its deposition into lysosomes from autophagic vacuoles.\",\n      \"method\": \"Lentiviral gene transfer in mouse brain, subcellular fractionation, immunoblotting, transgenic mouse models\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — lentiviral overexpression and pharmacological inhibition with defined cellular phenotype and subcellular fractionation\",\n      \"pmids\": [\"23787811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Loss of GBA (glucocerebrosidase) function increases SNCA levels by inhibiting the autophagic pathway; this occurs through PPP2A (protein phosphatase 2A) inactivation via Tyr307 phosphorylation, leading to decreased BECN1 expression; activating PPP2A with C2-ceramide or inducing autophagy with rapamycin reverses GBA knockdown-induced SNCA accumulation.\",\n      \"method\": \"GBA knockdown in SK-N-SH neuroblastoma cells and primary rat cortical neurons, plus in vivo rat striatum; pharmacological rescue experiments; immunoblotting\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple cell models plus in vivo, pharmacological and genetic epistasis, multiple orthogonal methods\",\n      \"pmids\": [\"26378614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DNA methylation at SNCA intron 1 regulates SNCA transcription; targeted hypermethylation of intron 1 using a CRISPR-dCas9-DNMT3A system in hiPSC-derived dopaminergic neurons from a PD patient with SNCA triplication reduces SNCA mRNA and protein levels, and rescues disease-related phenotypes including mitochondrial ROS production and reduced cellular viability.\",\n      \"method\": \"Lentiviral CRISPR-dCas9-DNMT3A delivery in hiPSC-derived dopaminergic neurons, qPCR, immunoblotting, mitochondrial ROS assay, cell viability assay\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct epigenetic editing with functional phenotypic rescue in human patient-derived neurons, multiple orthogonal readouts\",\n      \"pmids\": [\"30266652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CRISPR/Cas9n-mediated deletion of SNCA in human embryonic stem cell-derived midbrain dopaminergic neurons confers resistance to seeding of Lewy-like pathology by recombinant alpha-synuclein preformed fibrils (PFFs), as measured by reduced phospho-Ser129-alpha-synuclein (pS129-αSyn) aggregates; this demonstrates a gene dose-dependent requirement for endogenous SNCA in template-directed fibril propagation.\",\n      \"method\": \"CRISPR/Cas9n gene editing, hESC differentiation to mDA neurons, PFF seeding assay, immunofluorescence for pS129-αSyn\",\n      \"journal\": \"The European journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with defined mechanistic phenotype (fibril seeding), isogenic comparison of +/+, +/- and -/- genotypes\",\n      \"pmids\": [\"30472757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SNCA A30G mutation causes familial Parkinson's disease; biophysical characterization shows A30G has a local effect on the intrinsically disordered structure of alpha-synuclein, slightly perturbs membrane binding, and promotes fibril formation compared to wild-type.\",\n      \"method\": \"Whole-exome sequencing for disease segregation; NMR spectroscopy, circular dichroism, and fibril formation assays for biophysical characterization\",\n      \"journal\": \"Movement disorders\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biophysical characterization with multiple methods (NMR, CD, fibril assays) combined with genetic disease segregation in three families\",\n      \"pmids\": [\"33617693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SNCA is degraded predominantly via the autophagy-lysosome pathway (ALP) in oligodendrocytes under basal conditions; chaperone-mediated autophagy (CMA) is upregulated to remove pathological SNCA conformers (seeded by pre-formed fibrils), and augmentation of CMA or macroautophagy accelerates clearance of pathological SNCA assemblies.\",\n      \"method\": \"Pharmacological and siRNA-mediated modulation of autophagy and proteasome pathways in primary oligodendrocytes and oligodendroglial cell lines; in vitro CMA assay with rat brain lysosomes; PFF seeding model\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple genetic and pharmacological interventions, in vitro CMA reconstitution, multiple cell models\",\n      \"pmids\": [\"35000546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SNCA (alpha-synuclein) gain of function in PARK4 (SNCA duplication) leads to downregulation of complexin 1 (CPLX1) in blood, and there is an inverse mutual regulation between SNCA and CPLX1 mRNA levels; SNCA overexpression also impairs stimulus-triggered platelet degranulation.\",\n      \"method\": \"RNA-seq profiling and qRT-PCR validation in blood from PARK4 mutation carriers; platelet degranulation assay; CPLX1 SNP association analysis\",\n      \"journal\": \"Disease models & mechanisms\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — human patient blood samples with RNA-seq and functional platelet assays, but mechanism of SNCA-CPLX1 interaction not fully resolved\",\n      \"pmids\": [\"28108469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Recombinant human pro-CTSD (cathepsin D) is endocytosed by neuronal cells, correctly targeted to lysosomes, and matured to an enzymatically active protease that enhances clearance of insoluble SNCA conformers in iPSC-derived dopaminergic neurons from PD patients with the SNCA A53T mutation and in ctsd-deficient mouse brain neurons.\",\n      \"method\": \"Recombinant protein treatment of iPSC-derived neurons and primary murine neurons; immunoblotting, immunofluorescence, structured illumination microscopy; in vivo intracranial dosing in ctsd KO mice\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstituted enzyme activity, multiple model systems (human iPSC-derived neurons and in vivo mouse), clear mechanistic readout\",\n      \"pmids\": [\"35287553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM of alpha-synuclein filaments from juvenile-onset synucleinopathy (JOS) caused by a 21-nucleotide SNCA duplication reveals a new alpha-synuclein fold (residues 36-100 forming a compact core plus two disconnected density islands A and B of mixed sequences) distinct from Lewy body disease and MSA folds; a non-proteinaceous cofactor is bound between the core and island A, and in vitro assembly of recombinant mutant protein yields structures distinct from JOS filaments.\",\n      \"method\": \"Electron cryo-microscopy (cryo-EM) structure determination of sarkosyl-insoluble filaments from frontal cortex; in vitro fibril assembly of recombinant wild-type and mutant alpha-synuclein\",\n      \"journal\": \"Acta neuropathologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution cryo-EM structure with in vitro reconstitution, defines distinct disease-specific fold and cofactor binding\",\n      \"pmids\": [\"36847833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"P2RX4 activation mediates piperine-induced promotion of autophagy flux (via enhanced autophagosome-lysosome membrane fusion), which degrades pathological SNCA in SK-N-SH cells and in Thy1-SNCA transgenic mice; tandem mass tag proteomics identified P2RX4 as the key effector of this autophagy promotion.\",\n      \"method\": \"Pharmacological treatment of SNCA-overexpressing cells and transgenic mice, tandem mass tag proteomics, autophagy flux assays (mRFP-GFP-LC3), immunoblotting, behavioral assays\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — proteomics-identified target with pharmacological validation in cells and in vivo, multiple mechanistic readouts\",\n      \"pmids\": [\"34092198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Overexpression of SNCA-AS1 (the antisense transcript of SNCA) upregulates both SNCA mRNA and alpha-synuclein protein, and the SNCA-AS1/SNCA co-regulatory axis impacts neurite extension, GABAergic and dopaminergic synapse biology, and cellular senescence pathways.\",\n      \"method\": \"SNCA-AS1 overexpression and knockdown in neuronal cells, RNA-sequencing transcriptomic analysis, qRT-PCR validation\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct transcriptomic analysis with gain and loss of function, but downstream mechanisms are inferred from pathway analysis\",\n      \"pmids\": [\"34799977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PD patient-derived L1CAM-purified (neurogenic) extracellular vesicles carrying novel_miR_44438 promote alpha-synuclein (SNCA) accumulation in neurons; novel_miR_44438 directly targets NDST1 mRNA, inhibits heparan sulfate function, and thereby prevents exosome biogenesis and SNCA release from exosomes.\",\n      \"method\": \"EV immunoprecipitation from patient plasma, intrastriatal injection in SNCA-A53T transgenic mice, miRNA profiling, luciferase reporter assay for NDST1 targeting, immunohistochemistry\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo model with molecular target validation by luciferase assay, but single lab study\",\n      \"pmids\": [\"35596947\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SNCA encodes alpha-synuclein, a natively unfolded presynaptic protein that localizes to synaptic terminals and membranes; it is the major component of Lewy bodies in Parkinson's disease, where point mutations, duplications, and triplications cause dose-dependent aggregation and neurodegeneration; its intracellular levels are regulated by autophagy (including CMA and macroautophagy mediated by CTSD and PPP2A/GBA pathways), ABL1 kinase activity, DNA methylation at intron 1, and the antisense transcript SNCA-AS1, while disease-specific filament folds (revealed by cryo-EM) involve a compact core (residues 36–100) bound to a non-proteinaceous cofactor and are distinct for different synucleinopathies.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify each paper, then extract discoveries only from KEEP papers.\n\n**Classification:**\n- Papers 1-9, 11-12, 14-15, 18-19, 21, 24-26, 28-32, 35-38, 40-41, 43, 45-46, 48-50, 56, 65-67, 74-76, 78-79, 80-81, 83, 85-87, 91-92, 96-98: EXCLUDE (PD-1/PDCD1 immune checkpoint, not SNCA)\n- Paper 93 (SNCA-AS1): EXCLUDE (alt-locus product, antisense transcript, not the canonical protein)\n- Paper 72 (LncRNA-UCA1): EXCLUDE (about lncRNA UCA1 upregulating SNCA expression, not mechanistic study of SNCA protein itself — though borderline, it's primarily about UCA1)\n- Papers 10, 13, 16, 17, 20, 22, 23, 27, 33, 34, 39, 42, 44, 47, 51-55, 57-64, 68-71, 73, 77, 82, 84, 88-90, 94-95, 99-100: KEEP (SNCA/α-synuclein related)\n- Additional papers 1-3, 5-9, 12-16, 18, 20, 23-30: KEEP\n- Additional paper 4: EXCLUDE (about PINK1/Parkin, not SNCA mechanistically)\n- Additional paper 11: EXCLUDE (general cDNA cloning)\n- Additional papers 17, 19, 21, 22: EXCLUDE (PD-L1/PD-1 or general interactome, not SNCA mechanistic)\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"SNCA (NACP) was molecularly cloned as the precursor of NAC (non-Aβ component of AD amyloid), a 140-amino-acid protein (Mr ~19 kDa) found in the cytosolic fraction of brain homogenates and identified as a second component of purified AD amyloid; its NAC peptide sequence has strong β-structure-forming tendency consistent with amyloid association.\",\n      \"method\": \"cDNA cloning, amino acid sequencing, immunoblot, immunohistochemistry, secondary structure prediction\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original molecular cloning with biochemical validation, foundational paper >1000 citations\",\n      \"pmids\": [\"8248242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Human NACP/α-synuclein is a natively unfolded protein: it has a Stokes radius (34 Å) and sedimentation coefficient (1.7S) inconsistent with a globular fold, lacks significant secondary structure by CD and FTIR, has no hydrophobic core, and exists as rapidly equilibrating extended conformers—properties unchanged by boiling, pH, salt, or denaturants.\",\n      \"method\": \"Analytical ultracentrifugation, circular dichroism (CD), FTIR, UV spectroscopy, gel filtration\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal biophysical methods, >1200 citations, foundational structural characterization\",\n      \"pmids\": [\"8901511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"NACP/α-synuclein is a presynaptic protein colocalized with synaptophysin-immunoreactive structures; in Alzheimer's disease brain its concentration per synaptic structure increases while overall synaptic number decreases, and NAC immunoreactivity is found in the amyloid core of neuritic/diffuse plaques, implicating SNCA in amyloid formation.\",\n      \"method\": \"Semiquantitative immunoblot, confocal immunofluorescence, computer-aided morphometry\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — immunohistochemical localization with quantitative morphometry, replicated in multiple brain regions\",\n      \"pmids\": [\"8546207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The SNCA/NACP gene is the human homolog of rat synuclein, maps to chromosome 4, and is expressed as at least three alternatively spliced transcripts in lymphocytes; sequencing the entire coding region in 26 familial early-onset AD patients found no mutations.\",\n      \"method\": \"Homology search, chromosomal mapping, RT-PCR, direct sequencing\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic mapping with sequencing, foundational genomic characterization\",\n      \"pmids\": [\"7601450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"A missense mutation (A53T) in the SNCA gene co-segregates with autosomal dominant Parkinson's disease in an Italian kindred and three unrelated Greek families, identifying SNCA as the first gene causally linked to PD.\",\n      \"method\": \"Linkage analysis, mutation screening by sequencing, family-based genetic study\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — co-segregation in multiple independent families, >6600 citations, foundational discovery\",\n      \"pmids\": [\"9197268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"NACP/α-synuclein immunoreactivity is present in Lewy bodies and degenerating neurites in sporadic Parkinson's disease brain; all ubiquitin-immunoreactive Lewy bodies are also NACP-immunoreactive, establishing SNCA as a core component of Lewy bodies.\",\n      \"method\": \"Immunohistochemistry with anti-NACP and anti-ubiquitin antibodies on serial sections\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — double-label immunohistochemistry on serial sections, replicated across multiple PD cases\",\n      \"pmids\": [\"9547168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"NACP/α-synuclein expression is upregulated during phorbol ester-induced megakaryocytic differentiation in K562 cells while β-synuclein is downregulated; in platelets, NACP is loosely associated with the plasma membrane, endomembrane system, and membranes of secretory α-granules, demonstrating membrane association in a non-neuronal context.\",\n      \"method\": \"Immunoblot, immunogold electron microscopy, cell differentiation assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct subcellular localization by immunogold EM with differentiation context\",\n      \"pmids\": [\"9299413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"A30P mutation in SNCA is identified in a German family with Parkinson's disease, establishing a second causative point mutation in α-synuclein.\",\n      \"method\": \"Mutation screening/sequencing, family genetic study\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — co-segregation in PD family, independently replicated disease-causing mutation\",\n      \"pmids\": [\"9462735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"NACP/α-synuclein shows transient upregulation and redistribution around cerebral blood vessels after 5-min ischemia in gerbil hippocampal CA1 subfield, with development of unusual tubal and chain-like NACP-positive structures at 6 months, implicating SNCA in ischemic pathogenesis.\",\n      \"method\": \"Immunohistochemistry at multiple time points after ischemia\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single-method immunohistochemical observation, single lab\",\n      \"pmids\": [\"9555070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Expression of human α-synuclein in Drosophila causes dopaminergic neuron loss; directed expression of the molecular chaperone Hsp70 prevented this neuronal loss, and inhibition of endogenous chaperone activity accelerated α-synuclein toxicity—demonstrating that chaperone activity modulates SNCA-mediated neurodegeneration.\",\n      \"method\": \"Transgenic Drosophila, directed expression, dopaminergic neuron counting, genetic epistasis\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in established model organism, bidirectional chaperone manipulation, ~1000 citations\",\n      \"pmids\": [\"11823645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Dopamine and related catecholamines inhibit α-synuclein fibril formation by oxidative ligation to the protein, selectively stabilizing the protofibril intermediate (preventing protofibril-to-fibril conversion), providing a mechanistic explanation for the dopaminergic selectivity of α-synuclein-associated neurotoxicity.\",\n      \"method\": \"In vitro fibril formation assay, compound library screen, biochemical characterization of dopamine–α-synuclein adducts\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution assay with chemical mechanism identified, >900 citations\",\n      \"pmids\": [\"11701929\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"α-Synuclein is selectively and extensively phosphorylated at Ser129 in synucleinopathy lesions (PD, DLB, MSA); phosphorylation at Ser129 promotes fibril formation in vitro, identifying this modification as the dominant pathological post-translational modification.\",\n      \"method\": \"Mass spectrometry, phospho-specific antibody, in vitro fibril formation assay\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — MS identification of modification site plus in vitro functional validation, >1700 citations\",\n      \"pmids\": [\"11813001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Mutant forms of α-synuclein associated with familial Parkinson's disease form annular protofibrils morphologically resembling pore-forming bacterial toxins, suggesting inappropriate membrane permeabilization as a pathogenic mechanism.\",\n      \"method\": \"Electron microscopy of recombinant protein assemblies, structural comparison\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct structural visualization of protofibril morphology, >1000 citations\",\n      \"pmids\": [\"12124613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Triplication (four copies) of the SNCA locus causes early-onset Parkinson's disease with dementia, establishing that increased gene dosage of wild-type α-synuclein alone is sufficient to cause disease.\",\n      \"method\": \"Genomic dosage analysis, FISH, linkage analysis in large kindred\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genomic dosage determination in disease kindred, >3400 citations\",\n      \"pmids\": [\"14593171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The E46K mutation in SNCA causes autosomal dominant Parkinson's disease and Lewy body dementia; Lewy bodies in affected individuals are immunoreactive to α-synuclein and ubiquitin, establishing E46K as a third causative SNCA point mutation.\",\n      \"method\": \"SNCA gene sequencing, neuropathological examination, family co-segregation analysis\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — co-segregation with disease plus neuropathological confirmation, >2100 citations\",\n      \"pmids\": [\"14755719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Duplication of the SNCA locus causes familial Parkinson's disease with a clinical phenotype resembling idiopathic PD (late onset, slow progression, no prominent dementia), contrasting with the more severe triplication phenotype—establishing a gene dosage–phenotype relationship.\",\n      \"method\": \"Semiquantitative PCR, FISH in peripheral leukocytes, clinical characterization\",\n      \"journal\": \"Lancet (London, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genomic dosage determination with phenotypic correlation, >1600 citations\",\n      \"pmids\": [\"15451224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Wild-type α-synuclein is normally degraded via the chaperone-mediated autophagy (CMA) pathway; pathogenic A53T and A30P mutants bind the lysosomal CMA receptor but act as uptake blockers, inhibiting their own degradation and that of other CMA substrates.\",\n      \"method\": \"Lysosomal uptake assay, receptor-binding assay, in vitro CMA reconstitution\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of CMA pathway with mutagenesis comparison, >1600 citations\",\n      \"pmids\": [\"15333840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Extracellular aggregated α-synuclein activates microglia in primary mesencephalic neuron-glia cultures; microglial activation enhances dopaminergic neurodegeneration through phagocytosis of α-synuclein and NADPH oxidase-dependent reactive oxygen species production.\",\n      \"method\": \"Primary mesencephalic culture, microglial phagocytosis assay, NADPH oxidase inhibition, dopaminergic neuron counting\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection in primary culture with pharmacological inhibition, >1000 citations\",\n      \"pmids\": [\"15791003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"α-Synuclein immunoreactive inclusions are present in neurons of the gastric submucosal Meissner plexus and myenteric Auerbach plexus in individuals staged for PD-related brain pathology, suggesting enteric nervous system involvement and a possible route for pathogen-induced α-synuclein misfolding spreading from gut to brain.\",\n      \"method\": \"Immunocytochemistry on cryosections and paraffin sections of gastric tissue, staging correlation\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — direct immunohistochemical localization correlated with brain staging, >1000 citations\",\n      \"pmids\": [\"16330147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"α-Synuclein accumulation in yeast causes an early block in ER-to-Golgi vesicular trafficking; a genome-wide screen identified Rab GTPase Ypt1p (mammalian Rab1) as the key modifier; overexpression of Rab1 protected against α-synuclein-induced dopaminergic neuron loss in C. elegans and rat neuron models.\",\n      \"method\": \"Yeast genome-wide modifier screen, ER-to-Golgi trafficking assay, C. elegans dopaminergic neuron counting, rat neuron culture\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide epistasis screen plus cross-species validation, >1100 citations\",\n      \"pmids\": [\"16794039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Comprehensive inventory of α-synuclein modifications in Lewy bodies revealed that Ser129 phosphorylation is the predominant modification; ubiquitination occurs at Lys12, 21, and 23 and specific C-terminal truncations at Asp115, Asp119, Asn122, Tyr133, Asp135; ubiquitination appears secondary to phosphorylation and deposition.\",\n      \"method\": \"2D immunoblot, sandwich ELISA with modification-specific antibodies, tandem mass spectrometry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — MS mapping of modification sites with multiple orthogonal methods, >1100 citations\",\n      \"pmids\": [\"16847063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Patients homozygous for SNCA duplication show earlier onset and more severe cognitive impairment than heterozygotes, and biochemical analysis demonstrates that phosphorylated α-synuclein accumulates in the sarkosyl-insoluble urea-extracted fraction of brain, establishing a gene dosage–phosphorylation–aggregation relationship.\",\n      \"method\": \"Quantitative PCR for gene dosage, immunoblot of brain fractions, clinical characterization\",\n      \"journal\": \"Archives of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical fractionation combined with genetic dosage determination\",\n      \"pmids\": [\"18413475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"α-Synuclein is transmitted from affected neurons to neighboring neurons and to engrafted neuronal precursor cells via endocytosis, forming Lewy-like inclusions in recipient cells; lysosomal dysfunction promotes accumulation of transmitted α-synuclein; recipient cells show apoptotic markers (nuclear fragmentation, caspase 3 activation).\",\n      \"method\": \"Co-culture transmission assay, endocytosis inhibition, transgenic mouse model grafting, caspase activity assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-to-cell transmission demonstrated in vitro and in vivo with mechanistic dissection, >1100 citations\",\n      \"pmids\": [\"19651612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"α-Synuclein directly binds the SNARE protein synaptobrevin-2/VAMP2 and promotes SNARE-complex assembly; triple-knockout mice lacking all synucleins develop age-dependent neurological impairments with decreased SNARE-complex assembly, establishing α-synuclein as a non-classical chaperone for SNARE-complex assembly.\",\n      \"method\": \"Recombinant protein binding assay, in vitro SNARE-complex assembly assay, triple-knockout mouse phenotyping, brain biochemistry\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of SNARE assembly plus genetic loss-of-function in mice, >1400 citations\",\n      \"pmids\": [\"20798282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Endogenous α-synuclein isolated under non-denaturing conditions from neuronal and non-neuronal cell lines, brain tissue, and living human cells exists predominantly as a helically folded tetramer (~58 kDa); unlike recombinant monomers, native tetramers show α-helical structure without lipid addition, have greater lipid-binding capacity, and undergo little amyloid-like aggregation—suggesting that tetramer destabilization precedes pathological aggregation.\",\n      \"method\": \"Analytical ultracentrifugation, scanning transmission EM, in vivo crosslinking, CD spectroscopy, in vitro aggregation assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple structural methods on endogenous protein, functional aggregation comparison, >1000 citations\",\n      \"pmids\": [\"21841800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Functional loss of GD-linked glucocerebrosidase (GCase) in primary neurons and human iPSC-derived neurons causes lysosomal degradation impairment and α-synuclein accumulation; GCase substrate glucosylceramide (GlcCer) directly stabilizes soluble oligomeric α-synuclein intermediates in vitro; conversely, α-synuclein inhibits normal GCase lysosomal activity, forming a bidirectional pathogenic feedback loop.\",\n      \"method\": \"iPSC-derived neuron culture, in vitro GlcCer–α-synuclein aggregation assay, GCase activity assay in PD brain\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution plus iPSC neurons plus human PD brain validation, >1100 citations\",\n      \"pmids\": [\"21700325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ABL1 tyrosine kinase is activated in PD brains and by lentiviral SNCA expression in mouse substantia nigra; lentiviral Abl expression increases SNCA levels; ABL1 inhibition with nilotinib decreases ABL1 activity and facilitates autophagic clearance of SNCA, with subcellular fractionation showing movement of SNCA from autophagic vacuoles to lysosomes.\",\n      \"method\": \"Lentiviral gene transfer in mice, subcellular fractionation, nilotinib treatment, transgenic mouse model\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional genetic manipulation (overexpression and inhibition) with subcellular fractionation\",\n      \"pmids\": [\"23787811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Loss of GBA function in neuroblastoma cells and rat striatum leads to SNCA accumulation via inhibition of autophagy; this is mediated through PPP2A (protein phosphatase 2A) inactivation via Tyr307 phosphorylation, which suppresses BECN1 expression; PPP2A activation with C2-ceramide or rapamycin reverses GBA knockdown-induced SNCA accumulation.\",\n      \"method\": \"siRNA knockdown, glucocerebrosidase inhibition, PPP2A activity assay, pharmacological rescue in neuroblastoma cells and rat striatum\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway from GBA to PPP2A to autophagy to SNCA with pharmacological validation\",\n      \"pmids\": [\"26378614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"α-Synuclein assemblies of distinct conformational strains (oligomers, ribbons, fibrils) produce different histopathological and behavioral phenotypes after brain injection in rats; fibrils are the major toxic strain causing progressive motor impairment and cell death; ribbons produce a distinct phenotype with both PD and MSA traits; α-synuclein assemblies can cross the blood-brain barrier after intravenous injection and amplify in vivo.\",\n      \"method\": \"Intracerebral and intravenous injection of structurally defined α-synuclein assemblies, behavioral testing, neuropathology, in vivo amplification assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic comparison of structurally defined strains with multiple functional readouts, >900 citations\",\n      \"pmids\": [\"26061766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Targeted DNA methylation editing at SNCA intron 1 using a dCas9-DNMT3A lentiviral system causes fine-tuned downregulation of SNCA mRNA and protein in hiPSC-derived dopaminergic neurons from a PD patient with SNCA triplication; this reduction rescues disease-related cellular phenotypes including mitochondrial ROS production and reduced cell viability, establishing intron 1 DNA methylation as a regulator of SNCA transcription.\",\n      \"method\": \"CRISPR-dCas9-DNMT3A epigenome editing, hiPSC-derived dopaminergic neurons, qRT-PCR, Western blot, ROS assay, cell viability assay\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — targeted epigenome editing with functional rescue in patient-derived neurons, multiple outcome measures\",\n      \"pmids\": [\"30266652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CRISPR/Cas9n-mediated deletion of the endogenous SNCA gene in human embryonic stem cells confers dose-dependent resistance to α-synuclein preformed fibril (PFF)-induced Lewy-like pathology (pS129-αSyn aggregates) in mDA neurons, demonstrating that endogenous SNCA is required for seeded aggregation.\",\n      \"method\": \"CRISPR/Cas9n gene editing, hESC differentiation to mDA neurons, PFF seeding assay, phospho-α-synuclein immunofluorescence\",\n      \"journal\": \"The European journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean allele-dosage genetic deletion with defined seeding phenotype\",\n      \"pmids\": [\"30472757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The novel SNCA A30G mutation causes familial PD; biophysical characterization shows A30G has a local effect on the intrinsically disordered structure of α-synuclein, slightly perturbs membrane binding, and promotes fibril formation in vitro.\",\n      \"method\": \"Whole exome sequencing, haplotype analysis, NMR/biophysical characterization of recombinant A30G αSyn, fibril formation assay\",\n      \"journal\": \"Movement disorders\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — biophysical characterization of mutant protein with multiple methods; single lab\",\n      \"pmids\": [\"33617693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Piperine (PIP) promotes autophagy flux via P2RX4 activation in SNCA-overexpression PD models; tandem mass tag proteomics identified P2RX4 as the key mediator; PIP enhanced autophagosome-lysosome membrane fusion and degradation of pathological SNCA in SK-N-SH cells and Thy1-SNCA transgenic mice, attenuating olfactory and motor deficits.\",\n      \"method\": \"TMT proteomics, autophagy flux assay (mRFP-GFP-LC3), transgenic mouse behavioral testing, siRNA knockdown of P2RX4\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — proteomics-identified target validated by genetic knockdown and in vivo rescue\",\n      \"pmids\": [\"34092198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SNCA triplication midbrain organoids derived from patient iPSCs exhibit elevated α-synuclein levels and age-dependent accumulation of oligomeric and phosphorylated α-synuclein in both neurons and glial cells, correlating with selective reduction in dopaminergic neuron numbers, establishing a 3D model of synucleinopathy.\",\n      \"method\": \"iPSC-derived midbrain organoids, CRISPR isogenic correction, phospho-α-synuclein immunofluorescence, dopaminergic neuron quantification\",\n      \"journal\": \"Brain communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isogenic CRISPR-corrected control with longitudinal organoid characterization\",\n      \"pmids\": [\"34632384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Recombinant human pro-CTSD (cathepsin D) is endocytosed by neuronal cells, targeted to lysosomes, and matured to active protease; application to iPSC-derived dopaminergic neurons from PD patients with SNCA A53T mutation reduces insoluble SNCA; in ctsd-knockout mouse neurons and brain, rHsCTSD decreases pathological SNCA conformers and restores endo-lysosomal and autophagy function, establishing CTSD as a critical lysosomal protease for SNCA clearance.\",\n      \"method\": \"Enzyme replacement in iPSC-derived neurons and ctsd-KO mice, SIM, immunofluorescence, Western blot fractionation, lysosomal targeting assay\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO model plus enzyme replacement in patient-derived neurons and mouse brain, multiple orthogonal readouts\",\n      \"pmids\": [\"35287553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Macroautophagy and CMA are the primary degradation pathways for endogenous oligodendroglial SNCA and TPPP/p25A; TPPP/p25A contains a KFERQ-like motif enabling CMA degradation; in MSA-like settings with PFF seeding, PFF treatment impairs autophagic flux, TPPP/p25A inhibits macroautophagy, and CMA is upregulated to compensate; augmenting CMA or macroautophagy accelerates removal of pathological SNCA assemblies.\",\n      \"method\": \"siRNA knockdown of ATG5/LAMP2A, pharmacological modulation (rapamycin, AR7, 3-MA), lysosomal CMA assay with rat brain lysosomes, PFF seeding in oligodendroglial cells\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pathway manipulations with defined readouts in cellular and cell-free systems\",\n      \"pmids\": [\"35000546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"A 21-nucleotide duplication in SNCA (inserting MAAAEKT after residue 22, producing a 147-aa protein) causes juvenile-onset synucleinopathy; cryo-EM of sarkosyl-insoluble filaments from patient brain revealed a novel JOS α-synuclein fold (residues 36–100 as compact core, two disconnected density islands of mixed sequences, non-proteinaceous cofactor between core and island A) distinct from Lewy body disease and MSA folds; in vitro assembly of recombinant proteins yielded structures distinct from JOS filaments.\",\n      \"method\": \"Cryo-EM structure determination, genetic sequencing, in vitro fibril assembly, MS\",\n      \"journal\": \"Acta neuropathologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure of patient-derived filaments with in vitro validation\",\n      \"pmids\": [\"36847833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Blood RNA profiling of a SNCA gene duplication (PARK4) family revealed that CPLX1 (complexin 1) mRNA is inversely correlated with SNCA levels; SNCA gain of function impairs stimulus-triggered platelet degranulation; SNCA and CPLX1 mRNAs show inverse mutual regulation, and a CPLX1 3'-UTR SNP is significantly associated with PD risk.\",\n      \"method\": \"RNA-seq profiling of blood, platelet degranulation assay, qRT-PCR validation, genetic association analysis\",\n      \"journal\": \"Disease models & mechanisms\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional platelet assay combined with transcriptomic and genetic evidence in PARK4 kindred\",\n      \"pmids\": [\"28108469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SNCA multiplication (triplication) exacerbates neuronal nuclear aging: hiPSC-derived dopaminergic neurons from SNCA triplication patients show advanced aging signatures (altered heterochromatin, nuclear envelope markers, DNA damage, global DNA methylation) at juvenile stage; aged SNCA triplication neurons exhibit more α-synuclein aggregates per cell versus isogenic controls.\",\n      \"method\": \"hiPSC-derived neuron aging model (serial passaging of NPCs), immunofluorescence for heterochromatin/nuclear envelope markers, DNA damage assay, global DNA methylation analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isogenic hiPSC comparison with multiple nuclear aging markers\",\n      \"pmids\": [\"30304516\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SNCA encodes α-synuclein, a natively unfolded (or physiologically helically folded tetrameric) presynaptic protein that normally functions as a non-classical chaperone promoting SNARE-complex assembly via direct binding to synaptobrevin-2/VAMP2; it is degraded primarily through chaperone-mediated autophagy and the autophagy-lysosome pathway (with CTSD as a key lysosomal protease and GCase/GlcCer regulating lysosomal function in a bidirectional loop with α-synuclein); pathogenic point mutations (A53T, A30P, E46K, A30G), gene duplications, or triplications cause α-synuclein to misfold, accumulate as phospho-Ser129 species, form strain-specific amyloid filament structures that block ER-to-Golgi trafficking, activate microglia via NADPH oxidase, propagate between cells via endocytosis, and deposit as Lewy bodies—with dopamine oxidative ligation to α-synuclein stabilizing toxic protofibrillar intermediates and chaperones (Hsp70) suppressing dopaminergic neurodegeneration.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"SNCA encodes alpha-synuclein, a natively unfolded presynaptic protein that regulates vesicle dynamics at synaptic terminals and whose aggregation is the defining molecular event in synucleinopathies including Parkinson's disease and dementia with Lewy bodies. Alpha-synuclein is an intrinsically disordered monomer that associates loosely with plasma and vesicular membranes, and disease-linked point mutations (A53T, A30G) or gene multiplications promote fibril formation in a dose-dependent manner, with cryo-EM revealing disease-specific filament folds containing a compact core (residues 36–100) and a bound non-proteinaceous cofactor [PMID:8901511, PMID:33617693, PMID:36847833, PMID:18413475]. Intracellular alpha-synuclein levels are controlled by autophagy-lysosome pathways—including chaperone-mediated autophagy, macroautophagy regulated through the GBA/PPP2A/BECN1 axis, and cathepsin D-mediated lysosomal degradation—as well as transcriptionally by DNA methylation at SNCA intron 1 and the antisense transcript SNCA-AS1 [PMID:35000546, PMID:26378614, PMID:35287553, PMID:30266652, PMID:34799977]. Endogenous SNCA expression is required for template-directed propagation of Lewy-like pathology, and SNCA gene duplications and triplications cause autosomal dominant Lewy body disease with severity proportional to gene copy number [PMID:30472757, PMID:18413475].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Establishing that alpha-synuclein is intrinsically disordered resolved a basic structural question—how a protein lacking a hydrophobic core or stable fold could be a major brain protein—and set the framework for understanding its aggregation propensity.\",\n      \"evidence\": \"Multiple biophysical methods (CD, FTIR, analytical ultracentrifugation, SEC) on recombinant protein\",\n      \"pmids\": [\"8901511\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No atomic-resolution ensemble of the disordered state was available\", \"How disorder relates to membrane-bound conformational states was unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrating presynaptic localization and colocalization with synaptophysin defined alpha-synuclein as a nerve terminal protein, framing its function in synaptic biology and its relevance to neurodegenerative disease.\",\n      \"evidence\": \"Double immunocytochemistry and laser scanning confocal microscopy in human brain tissue\",\n      \"pmids\": [\"8546207\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise molecular function at the synapse was not identified\", \"Mechanism of synaptic enrichment was unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identifying alpha-synuclein as the major component of Lewy bodies in Parkinson's disease established the central pathological role of SNCA aggregation, superseding the earlier ubiquitin-centric view of Lewy body composition.\",\n      \"evidence\": \"Immunohistochemistry with anti-NACP and anti-ubiquitin antibodies on serial sections of sporadic PD brains; membrane association by immunogold EM in platelets\",\n      \"pmids\": [\"9547168\", \"9299413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SNCA aggregation is causative or consequential was unresolved\", \"Structure of pathological filaments was unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Gene dosage analysis of SNCA duplications showed that Lewy body disease severity scales with copy number, establishing a causal dose-response relationship between alpha-synuclein expression and neurodegeneration.\",\n      \"evidence\": \"Quantitative PCR for gene dosage and immunoblot of sarkosyl-insoluble fractions from autopsied patients with heterozygous and homozygous SNCA duplications\",\n      \"pmids\": [\"18413475\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which increased protein level triggers aggregation was not defined\", \"Whether transcriptional or post-translational regulation contributes to dosage effect was unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of a positive feedback loop between ABL1 kinase and SNCA—where SNCA overexpression activates ABL1, and ABL1 activity in turn raises SNCA levels—revealed a druggable kinase node in the autophagic clearance of alpha-synuclein.\",\n      \"evidence\": \"Lentiviral SNCA overexpression in mouse brain, subcellular fractionation, and Nilotinib pharmacological rescue in transgenic mice\",\n      \"pmids\": [\"23787811\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ABL1 substrate on SNCA or autophagy machinery not identified\", \"Long-term efficacy of ABL1 inhibition in neurodegeneration not established\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrating that GBA loss elevates SNCA through PPP2A inactivation and BECN1 downregulation linked glucocerebrosidase deficiency—the most common genetic risk factor for PD—to a defined autophagy signaling axis controlling alpha-synuclein levels.\",\n      \"evidence\": \"GBA knockdown in neuroblastoma cells, primary neurons, and rat striatum in vivo; pharmacological rescue with C2-ceramide and rapamycin\",\n      \"pmids\": [\"26378614\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this axis operates in human patient neurons was not tested\", \"Contribution relative to CMA-mediated SNCA clearance was not compared\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Targeted epigenetic editing showed that DNA methylation at SNCA intron 1 is a functional transcriptional switch: CRISPR-dCas9-DNMT3A hypermethylation reduced SNCA expression and rescued mitochondrial and viability phenotypes in patient-derived dopaminergic neurons, establishing an epigenetic therapeutic paradigm.\",\n      \"evidence\": \"Lentiviral CRISPR-dCas9-DNMT3A in hiPSC-derived dopaminergic neurons from an SNCA triplication patient; qPCR, immunoblot, ROS, and viability assays\",\n      \"pmids\": [\"30266652\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Durability of methylation and phenotypic rescue over long term unknown\", \"Delivery strategy for in vivo therapeutic application not addressed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"CRISPR knockout of SNCA in human midbrain dopaminergic neurons proved that endogenous alpha-synuclein is required for prion-like seeded aggregation, directly demonstrating a gene dose–dependent mechanism for pathology propagation.\",\n      \"evidence\": \"CRISPR/Cas9n gene editing in hESC-derived mDA neurons; PFF seeding assay with pS129-αSyn readout across +/+, +/−, and −/− genotypes\",\n      \"pmids\": [\"30472757\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether heterozygous reduction is sufficient to block seeding in vivo was not tested\", \"Mechanism by which endogenous SNCA templates fibril growth was not resolved at molecular level\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Characterization of SNCA clearance in oligodendrocytes demonstrated that both CMA and macroautophagy degrade alpha-synuclein, with CMA specifically upregulated to remove pathological conformers seeded by pre-formed fibrils, extending the autophagy-SNCA axis beyond neurons.\",\n      \"evidence\": \"Pharmacological and siRNA modulation of autophagy in primary oligodendrocytes; in vitro CMA reconstitution with rat brain lysosomes; PFF seeding\",\n      \"pmids\": [\"35000546\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether oligodendroglial CMA capacity is limiting in MSA pathogenesis was not determined\", \"Molecular recognition of pathological vs. native SNCA by CMA chaperones not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The A30G SNCA mutation was shown to cause familial PD and to promote fibril formation while subtly altering membrane binding, adding to the repertoire of disease-causing mutations and reinforcing that even minor perturbations in the disordered N-terminus suffice to shift aggregation kinetics.\",\n      \"evidence\": \"Whole-exome sequencing for family segregation; NMR, CD, and fibril formation assays on recombinant protein\",\n      \"pmids\": [\"33617693\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of accelerated aggregation at atomic resolution not resolved\", \"Whether A30G produces a distinct filament fold in vivo is unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of SNCA-AS1 as a positive regulator of SNCA expression added an antisense RNA layer to transcriptional control, with downstream effects on synaptic and senescence gene programs.\",\n      \"evidence\": \"Overexpression and knockdown of SNCA-AS1 in neuronal cells with RNA-seq and qRT-PCR validation\",\n      \"pmids\": [\"34799977\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which SNCA-AS1 upregulates sense SNCA mRNA not molecularly defined\", \"In vivo relevance not established\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Recombinant pro-CTSD delivered to neurons was shown to clear insoluble SNCA conformers after correct lysosomal targeting and activation, providing proof-of-concept for enzyme replacement therapy in synucleinopathies.\",\n      \"evidence\": \"Recombinant pro-CTSD treatment of iPSC-derived dopaminergic neurons (SNCA A53T) and ctsd KO mouse neurons in vivo; super-resolution microscopy\",\n      \"pmids\": [\"35287553\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CTSD directly cleaves aggregated SNCA or acts indirectly through general lysosomal activation is unclear\", \"Systemic delivery and blood-brain barrier crossing not demonstrated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Cryo-EM structures of alpha-synuclein filaments from juvenile-onset synucleinopathy revealed a disease-specific fold with a non-proteinaceous cofactor, establishing that distinct synucleinopathies produce structurally distinct strains—analogous to prion strains—and that in vitro assembly does not recapitulate in vivo folds.\",\n      \"evidence\": \"Cryo-EM of sarkosyl-insoluble filaments from patient frontal cortex; in vitro fibril assembly of recombinant WT and mutant protein for comparison\",\n      \"pmids\": [\"36847833\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the non-proteinaceous cofactor is unknown\", \"Whether the cofactor is required for pathological seeding is untested\", \"Structures for other synucleinopathies (e.g., PD with point mutations) not yet determined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the precise physiological function of alpha-synuclein at synapses, the identity of the non-proteinaceous cofactor in disease filaments, the molecular basis for strain-specific propagation, and whether reducing SNCA below a threshold is neuroprotective without impairing normal synaptic function.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Normal physiological function at the synapse remains poorly defined despite decades of research\", \"Identity of cryo-EM cofactor in disease filaments unknown\", \"Whether strain-specific folds dictate clinical phenotype causally is not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [3, 11]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [2, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 11]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [7, 12, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [7, 8, 12, 14, 16]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 6, 10, 11]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [1, 13, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ABL1\",\n      \"GBA\",\n      \"CTSD\",\n      \"PPP2CA\",\n      \"BECN1\",\n      \"CPLX1\",\n      \"NDST1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"α-Synuclein (SNCA) is a presynaptic, natively unfolded protein that functions as a non-classical chaperone promoting SNARE-complex assembly through direct binding to synaptobrevin-2/VAMP2, and whose misfolding and aggregation into phospho-Ser129-positive amyloid filaments underlies Parkinson's disease and related synucleinopathies [PMID:20798282, PMID:11813001]. Pathogenic point mutations (A53T, A30P, E46K, A30G), gene duplications, or triplications cause dose-dependent dopaminergic neurodegeneration by promoting fibril formation, blocking ER-to-Golgi trafficking, activating microglial NADPH oxidase, and propagating between neurons via endocytosis [PMID:9197268, PMID:16794039, PMID:15791003, PMID:19651612, PMID:14593171]. α-Synuclein is normally cleared through chaperone-mediated autophagy and the autophagy–lysosome pathway, where cathepsin D serves as a critical lysosomal protease and a bidirectional feedback loop with glucocerebrosidase/glucosylceramide modulates its lysosomal turnover [PMID:15333840, PMID:35287553, PMID:21700325]. Dopamine oxidatively ligates to α-synuclein and stabilizes toxic protofibrillar intermediates, providing a molecular basis for the selective vulnerability of dopaminergic neurons, while molecular chaperones such as Hsp70 suppress α-synuclein-mediated neurodegeneration [PMID:11701929, PMID:11823645].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Identification of SNCA as the precursor of NAC, a component of AD amyloid, established its amyloidogenic potential and provided the molecular clone needed for all subsequent functional studies.\",\n      \"evidence\": \"cDNA cloning, amino acid sequencing, immunoblot, and secondary structure prediction from human brain\",\n      \"pmids\": [\"8248242\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological function completely unknown\", \"Relationship to neurodegeneration beyond AD amyloid association unclear\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Biophysical characterization revealed α-synuclein is natively unfolded, lacking stable secondary structure or a hydrophobic core, which explained its unusual biochemical behavior and raised questions about how a disordered protein could form ordered aggregates.\",\n      \"evidence\": \"Analytical ultracentrifugation, CD, FTIR, gel filtration on recombinant protein\",\n      \"pmids\": [\"8901511\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether unfolded state is the sole physiological conformation (later challenged by tetramer hypothesis)\", \"Mechanism by which an unfolded protein nucleates amyloid not addressed\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"The A53T mutation co-segregating with autosomal dominant PD in multiple families, combined with α-synuclein immunoreactivity in all Lewy bodies, established SNCA as the first PD gene and its protein as the principal Lewy body component.\",\n      \"evidence\": \"Linkage analysis and sequencing in Italian/Greek PD families; double-label immunohistochemistry on sporadic PD brain\",\n      \"pmids\": [\"9197268\", \"9547168\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which A53T causes disease not yet known\", \"Whether wild-type α-synuclein contributes to sporadic PD unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Discovery of A30P as a second causative SNCA mutation confirmed that the gene is a bona fide PD locus and that multiple positions in α-synuclein's N-terminal repeat region are vulnerable to pathogenic substitution.\",\n      \"evidence\": \"Mutation screening and co-segregation in a German PD family\",\n      \"pmids\": [\"9462735\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for how A30P differs mechanistically from A53T unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Two discoveries resolved key aspects of α-synuclein toxicity: dopamine oxidative ligation stabilizes toxic protofibrillar intermediates (explaining dopaminergic selectivity), and Hsp70 chaperone activity suppresses α-synuclein-induced dopaminergic neuron loss (identifying the protein quality control axis as protective).\",\n      \"evidence\": \"In vitro fibril formation with dopamine-adduct characterization; transgenic Drosophila with Hsp70 co-expression and genetic epistasis\",\n      \"pmids\": [\"11701929\", \"11823645\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether dopamine-stabilized protofibrils are the toxic species in vivo unproven\", \"Hsp70 mechanism of action on α-synuclein (refolding vs disaggregation vs degradation) not defined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of Ser129 phosphorylation as the dominant pathological modification and visualization of annular protofibrillar structures for mutant α-synuclein established a post-translational and structural framework for synucleinopathy.\",\n      \"evidence\": \"Mass spectrometry and phospho-specific antibodies on disease brain; electron microscopy of recombinant mutant assemblies\",\n      \"pmids\": [\"11813001\", \"12124613\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Ser129 phosphorylation is causally required for aggregation or merely correlative in vivo\", \"Identity of the kinase(s) responsible in vivo not resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"SNCA locus triplication causing early-onset PD with dementia proved that increased dosage of wild-type α-synuclein alone suffices for disease, fundamentally reframing PD pathogenesis as a gene-dose problem.\",\n      \"evidence\": \"Genomic dosage analysis and FISH in a large Iowa kindred\",\n      \"pmids\": [\"14593171\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Threshold of expression increase needed for pathogenesis not defined\", \"Mechanism linking overexpression to selective dopaminergic vulnerability unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identification of E46K as a third causative mutation and SNCA duplication as a milder dose-dependent PD cause, together with discovery that wild-type α-synuclein is cleared via CMA while mutants block the pathway, connected genetic dose and mutant-specific toxicity to the lysosomal degradation axis.\",\n      \"evidence\": \"E46K family co-segregation with neuropathology; FISH for duplication; in vitro CMA reconstitution with lysosomal uptake and receptor-binding assays\",\n      \"pmids\": [\"14755719\", \"15451224\", \"15333840\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CMA blockade by mutant α-synuclein is sufficient for disease in vivo\", \"Relative contribution of CMA versus macroautophagy to α-synuclein clearance in neurons not quantified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"A yeast genome-wide screen identified Rab1-sensitive ER-to-Golgi trafficking as the primary pathway blocked by α-synuclein accumulation, validated across C. elegans and rat neurons, establishing vesicular trafficking disruption as a core cytotoxic mechanism.\",\n      \"evidence\": \"Genome-wide overexpression/deletion screen in yeast; ER-to-Golgi assay; cross-species rescue experiments\",\n      \"pmids\": [\"16794039\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ER-to-Golgi block is a direct stoichiometric effect of α-synuclein on vesicle fusion or indirect\", \"Mammalian Rab GTPases other than Rab1 that may compensate not explored\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstration that α-synuclein transmits from affected to naïve neurons via endocytosis and seeds Lewy-like inclusions in recipient cells established prion-like propagation as a disease mechanism.\",\n      \"evidence\": \"Co-culture transmission assay with endocytosis inhibition; grafting into transgenic mouse brain; caspase 3 activation in recipient cells\",\n      \"pmids\": [\"19651612\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor or uptake mechanism for α-synuclein entry into recipient cells not identified\", \"Whether propagation drives disease progression in human PD unproven\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Reconstitution of α-synuclein's physiological function showed it directly binds VAMP2 and promotes SNARE-complex assembly, with triple-synuclein knockout mice developing age-dependent neurological impairment, establishing α-synuclein as a presynaptic SNARE chaperone.\",\n      \"evidence\": \"Recombinant protein binding and SNARE assembly reconstitution; triple-knockout mouse phenotyping with brain biochemistry\",\n      \"pmids\": [\"20798282\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Redundancy among synuclein family members for SNARE chaperoning not fully dissected\", \"Whether loss of SNARE chaperone function contributes to PD pathogenesis distinct from gain-of-toxic-function\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Two parallel advances reshaped the field: endogenous α-synuclein exists as a helically folded tetramer resistant to aggregation (challenging the unfolded monomer paradigm), and GCase loss creates a bidirectional pathogenic loop where glucosylceramide stabilizes α-synuclein oligomers while α-synuclein inhibits GCase activity.\",\n      \"evidence\": \"Analytical ultracentrifugation and EM on endogenous protein; iPSC-derived neurons and in vitro GlcCer–α-synuclein aggregation assay with GCase activity in PD brain\",\n      \"pmids\": [\"21841800\", \"21700325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tetramer versus monomer debate not fully resolved—conditions of native isolation remain debated\", \"Quantitative contribution of GCase–α-synuclein loop to sporadic PD unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Injection of structurally defined α-synuclein strains (oligomers, ribbons, fibrils) into rat brain produced distinct pathological and behavioral phenotypes, establishing the prion strain concept for synucleinopathies and demonstrating that fibrils cross the blood-brain barrier.\",\n      \"evidence\": \"Intracerebral and intravenous injection of characterized assemblies; behavioral testing and neuropathology\",\n      \"pmids\": [\"26061766\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether strain-specific folds found in animal models correspond to human disease subtypes not confirmed\", \"Mechanism of blood-brain barrier crossing unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Epigenome editing at SNCA intron 1 using dCas9-DNMT3A rescued disease phenotypes in triplication patient-derived neurons, and CRISPR deletion of SNCA abolished PFF-seeded aggregation, together establishing intron 1 methylation as a transcriptional regulator and endogenous α-synuclein as required for seeded pathology.\",\n      \"evidence\": \"dCas9-DNMT3A lentiviral system in triplication iPSC-DA neurons; CRISPR/Cas9n SNCA knockout in hESC-derived mDA neurons with PFF seeding\",\n      \"pmids\": [\"30266652\", \"30472757\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Therapeutic window for methylation-based SNCA reduction not defined\", \"Whether complete SNCA elimination has long-term detrimental effects on synaptic function\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Recombinant cathepsin D replacement in iPSC-derived A53T neurons and ctsd-KO mice cleared pathological α-synuclein conformers and restored endo-lysosomal function, establishing CTSD as the critical lysosomal protease for α-synuclein degradation.\",\n      \"evidence\": \"Enzyme replacement therapy in patient iPSC-DA neurons and ctsd-KO mouse brain; SIM imaging, Western blot fractionation, lysosomal targeting assays\",\n      \"pmids\": [\"35287553\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CTSD is rate-limiting in sporadic PD lysosomes not established\", \"Delivery of recombinant CTSD to human brain not demonstrated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Cryo-EM of brain-derived filaments from a patient with a 21-nucleotide SNCA insertion revealed a novel α-synuclein fold distinct from Lewy body and MSA folds, with a non-proteinaceous cofactor, strengthening the concept that distinct structural polymorphs underlie distinct synucleinopathies.\",\n      \"evidence\": \"Cryo-EM structure determination of sarkosyl-insoluble filaments from JOS patient brain; comparison with in vitro assembled filaments\",\n      \"pmids\": [\"36847833\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the non-proteinaceous cofactor unknown\", \"Whether the JOS fold can be reproduced in vitro with the correct cofactor not achieved\", \"Structural basis for strain-specific toxicity not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of the physiological α-synuclein conformation in vivo (tetramer vs. monomer equilibrium), the receptor mediating cell-to-cell propagation, the structural determinants of strain-specific toxicity, and whether loss of SNARE chaperone function contributes to disease independently of toxic aggregation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Native quaternary state in living neurons remains debated\", \"No receptor for α-synuclein uptake during propagation identified\", \"Relative contribution of loss-of-function versus gain-of-toxic-function to PD not quantified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0044183\", \"supporting_discovery_ids\": [23]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [6, 24]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [6, 19]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [16, 34, 35]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [23, 37]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [16, 26, 27, 32, 34, 35]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 7, 13, 14, 15]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [19, 22]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"complexes\": [\n      \"SNARE complex (as chaperone, not stable subunit)\"\n    ],\n    \"partners\": [\n      \"VAMP2\",\n      \"GBA\",\n      \"CTSD\",\n      \"HSPA1A\",\n      \"CPLX1\",\n      \"RAB1A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}